AMINOQUINOLINE COMPOUNDS

COMPOSES A BASE D'AMINOQUINOLINE

English Abstract

This invention relates to treating inflammatory and immune diseases with
certain aminoquinoline compounds that bind to CXCR3 receptors. The
aminoquinoline compounds are covered by the formula (I) shown below. Each
variable is defined in the specification.

French Abstract

La présente invention concerne le traitement de maladies inflammatoires et immunes à l'aide de certains composés à base d'aminoquinoline qui se fixent aux récepteurs CXCR3. Ces composés à base d'aminoquinoline sont représentés par la formule générale (I) ci-dessous. Chaque variable de la formule est définie dans la partie descriptive de la présente demande.

Claims

WHAT IS CLAIMED IS:

1. A method for treating an inflammatory or immune disease, comprising
administering to a subject in need thereof an effective amount of a compound
of
formula (I):

Image

wherein
each ~ is a single bond or a double bond; provided that if one ~ is a double
bond, its neighboring ~ is not a double bond;
each of =X1-, =X2-, =X3-, and =X4-, independently, is -C=, -CR a, -N=, -N-, -S-
,
-O-, or a single bond; at most one of =X1-, =X2-, =X3-, and =X4- being a
single bond,
and at most two of =X1-, =X2-, =X3-, and =X4- being -N=, -N-, -S-, or -O-;
each of R1 and R2, independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, C1-C6 alkylamino, C1-C12 dialkylamino, arylamino,
diarylamino, -C(O)-NR b R b', -C(O)-OR b, -OC(O)-R b, -C(O)-R b, or halogen;
or R1
and R2 together are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl;
each of R3 and R4, independently, is H or -A-N(B)-D; and
each of R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C2-C8 alkenyl,
C2-
C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C1-
C6
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, NO2, CN, C1-C6 alkylamino, C1-C12 dialkylamino,
arylamino,
diarylamino, -C(O)-NR c R c, -C(O)-OR c, -OC(O)-R c, -C(O)-R c, halogen, or
deleted; or
R5 and R6 together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R6 and
R7
together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R7 and R8 together
are C5-
C7 cycloalkyl or C5-C7 heterocycloalkyl; provided that if R5 is deleted, =X1-
is -N=, -


58


S-, -O-, or a single bond; if R6 is deleted, =X2- is -N=, -S-, -O-, or a
single bond; if R7
is deleted, =X3- is -N=, -S-, -O-, or a single bond; and if R8 is deleted, =X4-
is -N=, -S-
-O-, or a single bond;
in which A is C1-C12 alkyl optionally containing 1-6 heteroatoms, C2-C12
alkenyl
optionally containing 1-6 heteroatoms, C2-C12 alkynyl optionally containing 1-
6
heteroatoms, aryl, heteroaryl, C1-C10 alkylsulfonyl, arylsulfonyl, C1-C10
alkylcarbonyl
containing 1-6 heteroatoms, C2-C20 alkylaryl optionally containing 1-6
heteroatoms,
C2-C20 arylalkyl optionally containing 1-6 heteroatoms, C2-C20 alkylheteroaryl
containing 1-6 heteroatoms, or C2-C20 heteroarylalkyl containing 1-6
heteroatoms;
B is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8
cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8 heterocycloalkenyl, aryl, or
heteroaryl; or
B and A together are C5-C7 heterocycloalkyl or heteroaryl; and D is H, aryl,
heteroaryl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8
cycloalkenyl, C3-C8 heterocycloalkyl, C3-C8 heterocycloalkenyl, -C(O)-R d, -
SO2-R d, -
C(S)-R d, -C(O)-NR d R d', -C(O)-OR d, -OC(O)-R d, -C(O)-SR d, or -SC(O)-R d;
or D
and A together are C5-C7 heterocycloalkyl or heteroaryl; each of R a, R b, R
b', R c, R c',
R d, and R d', independently, being H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, C3-C8
cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8
heterocycloalkenyl,
aryl, or heteroaryl; or R d and R d' together being C5-C7 heterocycloalkyl;
or a salt thereof.

2. The method of claim 1, wherein D is of formula (II),

Image

wherein
each ~ is a single bond or a double bond; provided that if one ~ is a double
bond, its neighboring ~ is not a double bond;
each of =X1'-, =X2'-, =X3'-, and =X4'-, independently, is -C=, -CR e-, -N=, -N-
,
-S-, -O-, or a single bond; at most one of =X1'-, =X2'-, =X3'-, and =X4'-,
being a


59


single bond, and at most two of =X1'-, =X2'-, =X3'-, and =X4'-, being -N=, -N-
, -S-, or
-O-;
each of R1' and R2', independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C3-C8 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, C1-C6 alkylamino, C1-C12 dialkylamino, arylamino,
diarylamino, -C(O)-NR f R f', -C(O)-OR f, -OC(O)-R f, -C(O)-R f, or halogen;
or R1' and
R2' together are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl;
each of R3', R4', R5', and R6', independently, is H, C1-C8 alkyl, C2-C8
alkenyl,
C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl,
C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy; C1-C6
alkylthio, arylthio, NH2, NO2, CN, C1-C6 alkylamino, C1-C12 dialkylamino,
arylamino,
diarylamino, -C(O)-NR g R g', -C(O)-OR g, -OC(O)-R g, -C(O)-R g, halogen, or
deleted;
or R3' and R4' together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R4'
and R5'
together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R5' and
R6'together are
C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; provided that if R3'is deleted,
=X1'- is -
N=, -S-, -O-, or a single bond; if R4' is deleted, =X2'- is -N=, -S-, -O-, or
a single
bond; if R5' is deleted, =X3'- is -N=, -S-, -O-, or a single bond; and if R6'
is deleted, =
X4'- is -N=, -S-, -O-, or a single bond;
in which each of R e, R f, R f', R g, and R g', independently, being H, C1-C8
alkyl, C2-C8
alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8
heterocycloalkyl,
C5-C8 heterocycloalkenyl, aryl, or heteroaryl.

3. The method of claim 1, wherein each of=X1-, =X2-, =X3-, and =X4-,
independently, is -C=, -CR a, -N=, -N-, -S-, or a single bond; each of R1 and
R2,
independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8
heterocycloalkyl, aryl, heteroaryl, C1-C6 alkoxy, aryloxy, heteroaryloxy, C1-
C6
alkylthio, arylamino, diarylamino, -C(O)-NR b R b', or -C(O)-R b; or R1 and R2
together
are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl; each of R5, R6, R7, and R8,
independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8
cycloalkyl, C5-
C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8 heterocycloalkenyl, OH, C1-C6
alkoxy, aryloxy, heteroaryloxy, C1-C6 alkylthio, arylthio, NO2, -C(O)-NR c R
c', -C(O)-




R c, halogen, or deleted; or R6 and R7 together are C5-C7 cycloalkyl or C5-C7
heterocycloalkyl; provided that if R5 is deleted, =X1- is -N=, -S-, or a
single bond; if
R6 is deleted, =X2- is -N=, -S-, or a single bond; if R7 is deleted, =X3- is -
N=, -S-, or
a single bond; and if R8 is deleted, =X4- is -N=, -S-, or a single bond; B is
H, C1-C8
alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, or heteroaryl; or B and A together
are C5-C7
heterocycloalkyl or heteroaryl; D is H, aryl, heteroaryl, C1-C8 alkyl, C3-C8
heterocycloalkyl, or -C(O)-R d; or D and A together are C5-C7 heterocycloalkyl
or
heteroaryl; and each of R a, R b, R b', R c, R c', R d, and R d',
independently, is H, C5-C8
cycloalkenyl, C5-C8 heterocycloalkenyl, aryl, or heteroaryl.

4. The method of claim 3, wherein each of =X1-, =X2-, =X3-, and =X4-,
independently, is -C=, -CR a, or -N=; each of R1 and R2, independently, is H,
C1-C8
alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C1-C6 alkoxy, aryloxy,
heteroaryloxy, or C1-
C6 alkylthio; or R1 and R2 together are C5-C8 cycloalkyl or C5-C8
heterocycloalkyl;
each of R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C2-C8 alkenyl,
C2-C8
alkynyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy, aryloxy, heteroaryloxy, C1-
C6
alkylthio, arylthio, halogen, or deleted; or R6 and R7 together are C5-C7
cycloalkyl or
C5-C7 heterocycloalkyl; provided that if R5 is deleted, =X1- is -N=; if R6 is
deleted, =
X2- is -N=; if R7 is deleted, =X3- is -N=; and if R8 is deleted, =X4- is -N=;
A is C1-C12
alkyl optionally containing 1-6 heteroatoms, C2-C12 alkenyl optionally
containing 1-6
heteroatoms, C2-C12 alkynyl optionally containing 1-6 heteroatoms, aryl, C1-
C10
alkylsulfonyl, arylsulfonyl, C1-C10 alkylcarbonyl containing 1-6 heteroatoms,
C2-C20
alkylaryl optionally containing 1-6 heteroatoms, or C2-C20 arylalkyl
optionally
containing 1-6 heteroatoms; D is H, aryl, heteroaryl, C1-C8 alkyl, C3-C8
heterocycloalkyl, or -C(O)-R d; and each of R a, R b, R b', R c, R c', R d,
and R d',
independently, is H, aryl, or heteroaryl.

5. The method of claim 4, wherein A is C1-C12 alkyl, arylsulfonyl, C1-C10
alkylcarbonyl containing 1-6 heteroatoms, C2-C20 arylalkyl, or A and B
together are
heteroaryl.

61




6. ~The method of claim 5, wherein each of =X1-, =X2-, =X3-, and =X4-,
independently, is -C=; each of R1 and R2, independently, is H or C1-C8 alkyl;
or R1
and R2 together are C5-C8 cycloalkyl; each of R5, R6, R7, and R8,
independently, is H,
C1-C8 alkyl, Cl-C6 alkoxy, or halogen; and B is H or B and A together are
heteroaryl.

7. ~The method of claim 4, wherein D is of formula (II),
Image~
wherein
each Image is a single bond or a double bond; provided that if one Image is a
double
bond, its neighboring Image is not a double bond;
each of =X1'-, =X2'-, =X3'-, and =X4'-, independently, is -C=, -CR c-, or -N=;
at
most two of =X1'-, =X2'-, =X3'-, and =X4'- being -N=;
each of R1' and R2', independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, aryl, C1-C6 alkoxy, aryloxy, heteroaryloxy, or C1-C6 alkylthio; or
R1' and R2'
together are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl; and
each of R3', R4', R5', and R6', independently, is H, C1-C8 alkyl, C2-C8
alkenyl,
C2-C8 alkynyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C5-
C6 alkylthio, arylthio, or halogen; or R4' and R5' together are C5-C7
cycloalkyl or C5-
C7 heterocycloalkyl;
in which R e is H, aryl, or heteroaryl.

8. ~The method of claim 7, wherein A is C1-C12 alkyl.

9. ~The method of claim 7, wherein A is C1-C12 alkyl containing 1-6
heteroatoms and optionally substituted with sulfonyl, C1-C6 alkylsulfonyl,
arylsulfonyl, or heteroarylsulfonyl.

62



10. The method of claim 7, wherein A is C2-C20 alkylaryl optionally
containing 1-6 heteroatoms.

11. The method of claim 7, wherein A is aryl, or A and B together are
heteroaryl.

12. The method of claim 8, wherein each of =X1-, =X2-, =X3-, and =X4-,
independently, is -C=; each of R1 and R2, independently, is H, C1-C8 alkyl, or
aryl; or
R1 and R2 together are C5-C8 cycloalkyl; each of R5, R6, R7, and R8,
independently, is
H, C1-C8 alkyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy, aryloxy, C1-C6
alkylthio,
or halogen; B is H or C1-C8 alkyl; each of =X1'-, =X2'-, =X3'-, and =X4'-,
independently, is -C=; each of R1' and R2', independently, is H, C1-C8 alkyl,
or aryl;
or R1' and R2' together are C5-C8 cycloalkyl; each of R3', R4', R5', and R6',
independently, is H, C1-C8 alkyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy,
aryloxy,
C1-C6 alkylthio, or halogen.

13. The method of claim 9, wherein each of =X1-, =X2-, =X3-, and =X4-,
independently, is -C=; each of R1 and R2, independently, is H or C1-C8 alkyl;
or R1
and R2 together are C5-C8 cycloalkyl; each of R5, R6, R7, and R8,
independently, is H,
C1-C8 alkyl, C1-C6 alkoxy, aryloxy, C1-C6 alkylthio, or halogen; B is H; each
of =X1'-,
=X2'-, =X3'-, and =X4'-, independently, is -C=; each of R1' and R2',
independently,
is H or C1-C8 alkyl; or R1' and R2' together are C5-C8 cycloalkyl; each of
R3', R4',
R5', and R6', independently, is H, C1-C8 alkyl, C1-C6 alkoxy, aryloxy, C1-C6
alkylthio,
or halogen.

14. The method of claim 10, wherein each of=X1-, =X2-, =X3-, and =X4-,
independently, is -C=; each of R1 and R2, independently, is H or C1-C8 alkyl;
each of
R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C1-C6 alkoxy, aryloxy,
or
halogen; B is H; each of =X1'-, =X2'-, =X3'-, and =X4'-, independently, is -
C=; each of
R1' and R2', independently, is H or C1-C8 alkyl; each of R3', R4', R5', and
R6',
independently, is H, C1-C8 alkyl, C1-C6 alkoxy, aryloxy, or halogen.

63



15. The method of claim 11, wherein each of =X1-, =X2-, =X3-, and =X4-,
independently, is -C=; each of R1 and R2, independently, is H or C1-C8 alkyl;
each of
R5, R6, R7, and R8, independently, is H or C1-C8 alkyl; B is H; or B and A
together are
heteroaryl; each of =X1'-, =X2'-, =X3'-, and =X4'-, independently, is -C=;
each of R1'
and R2', independently, is H or C1-C8 alkyl; each of R3', R4', R5', and R6',
independently, is H or C1-C8 alkyl.

16. A compound of formula (I):
Image
wherein
each Image is a single bond or a double bond; provided that if one Image is a
double
bond, its neighboring Image is not a double bond;
each of =X1-, =X2-, =X3-, and =X4-, independently, is -C=, -CR a , -N=, -N-, -
S-,
-O-, or a single bond; at most one of =X1-, =X2-, =X3-, and =X4- being a
single bond
and at most two of =X1-, =X2-, =X3-, and =X4- being -N=, -N-, -S-, or -O-;
each of R1 and R2, independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, C1-C6 alkylamino, C1-C12 dialkylamino, arylamino,
diarylamino, -C(O)-NR b R b', -OC(O)-R b, -C(O)-R b, or halogen; or R1 and R2
together are C5-C8 heterocycloalkyl;
each of R3 and R4, independently, is H or -A-N(B)-D; at most one of R3 and
R4 being H; and
each of R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C2-C8 alkenyl,
C2-
C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-
C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6

64


alkylthio, arylthio, NH2, NO2, CN, C1-C6 alkylamino, C1-C12 dialkylamino,
arylamino,
diarylamino, -C(O)-NR c R c', -C(O)-OR c, -OC(O)-R c, -C(O)-R c, halogen, or
deleted; or
R5 and R6 together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R6 and
R~
together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R7 and R8 together
are C5-
C7 cycloalkyl or C5-C7 heterocycloalkyl; provided that if R5 is deleted, =X1-
is -N=, -
S-, -O-, or a single bond; if R6 is deleted, =X2- is -N=, -S-, -O-, or a
single bond; if R7
is deleted, =X3- is -N=, -S-, -O-, or a single bond; and if R8 is deleted, =X4-
is -N=, -S-
-O-, or a single bond;
in which A is C1-C12 alkyl optionally containing 1-6 heteroatoms, C2-C12
alkenyl
optionally containing 1-6 heteroatoms, C2-C12 alkynyl optionally containing 1-
6
heteroatoms, aryl, heteroaryl, C1-C10 alkylsulfonyl, arylsulfonyl, C1-C10
alkylcarbonyl
containing 1-6 heteroatoms, C2-C20 alkylaryl optionally containing 1-6
heteroatoms,
C2-C20 arylalkyl optionally containing 1-6 heteroatoms, C2-C20 alkylheteroaryl
containing 1-6 heteroatoms, or C2-C20 heteroarylalkyl containing 1-6
heteroatoms;
B is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8
cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8 heterocycloalkenyl, aryl, or
heteroaryl; or
B and A together are heteroaryl; and D is H, aryl, heteroaryl, C1-C8 alkyl, C2-
C8
alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8
heterocycloalkyl,
C5-C8 heterocycloalkenyl, -C(O)-R d, -SO2-R d, -C(S)-R d, -C(O)-NR d R d', -
C(O)-
OR d, -OC(O)-R d, -C(O)-SR d, or -SC(O)-R d; or D and A together are
heteroaryl;
each of R a, R b, R b', R c, R c', R d, and R d', independently, being H, C1-
C8 alkyl, C2-C8
alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8
heterocycloalkyl,
C5-C8 heterocycloalkenyl, aryl, or heteroaryl; or R d and R d' together being
C5-C7
heterocycloalkyl;
or a salt thereof.

17. The compound of claim 16, wherein D is of formula (II),
Image




wherein
each ~ is a single bond or a double bond; provided that if one ~ is a double
bond, its neighboring ~ is not a double bond;
each of ~X1'-, ~X2'-, ~X3'-, and ~X4'-, independently, is -C=, -CR e-, -N=, -N-
,
-S-, -O-, or a single bond; at most one of ~X1'-, ~X2'-, ~X3'-, and ~X4'-,
being a
single bond, and at most two of ~X1'-, ~X2'-, ~X3'-, and ~X4'-, being -N=, -N-
, -S-, or
-O-;
each of R1' and R2', independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, C1-C6 alkylamino, C1-C12 dialkylamino, arylamino,
diarylamino, -C(O)-NR f R f', -OC(O)-R f, -C(O)-R f, or halogen; or R1' and
R2' together
are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl;
each of R3', R4', R5', and R6', independently, is H, C1-C8 alkyl, C2-C8
alkenyl,
C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl,
C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, NO2, CN, C1-C6 alkylamino, C1-C12 dialkylamino,
arylamino,
diarylamino, -C(O)-NR g R g', -C(O)-OR g, -OC(O)-R g, -C(O)-R g, halogen, or
deleted;
or R3' and R4' together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R4'
and R5'
together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R5' and R6'
together are
C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; provided that if R3' is deleted,
~X1'- is -
N=, -S-, -O-, or a single bond; if R4' is deleted, ~X2'- is -N=, -S-, -O-, or
a single
bond; if R5' is deleted, ~X3'- is -N=, -S-, -O-, or a single bond; and if R6'
is deleted, ~
X4'- is -N=, -S-, -O-, or a single bond;
in which each of R e, R f, R f', R g, and R g', independently, being H, C1-C8
alkyl, C2-C8
alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8
heterocycloalkyl,
C5-C8 heterocycloalkenyl, aryl, or heteroaryl.
18. The compound of claim 16, wherein each of ~X1-, ~X2-, ~X3-, and ~X4-
, independently, is -C=, -CR a-, -N=, -N-, -S-, or a single bond; each of R1
and R2,
independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8
heterocycloalkyl, aryl, heteroaryl, C1-C6 alkoxy, aryloxy, heteroaryloxy, C1-
C6
66




alkylthio, arylamino, diarylamino, -C(O)-NR b R b', or -C(O)-R b; or R1 and R2
together
are C5-C8 heterocycloalkyl; each of R5, R6, R7, and R8, independently, is H,
C1-C8
alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-
C8
heterocycloalkyl, C5-C8 heterocycloalkenyl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6 alkylthio, arylthio, NO2, -C(O)-NR c R c', -C(O)-R c,
halogen, or
deleted; or R6 and R7 together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl;
provided that if R5 is deleted, ~X1- is -N=, -S-, or a single bond; if R6 is
deleted, ~
X2- is -N=, -S-, or a single bond; if R7 is deleted, ~X3- is -N=, -S-, or a
single bond;
and if R8 is deleted, ~X4- is -N=, -S-, or a single bond; B is H, C1-C8 alkyl,
C2-C8
alkenyl, C2-C8 alkynyl, aryl, or heteroaryl; or B and A together are
heteroaryl; D is H,
aryl, heteroaryl, C3-C8 heterocycloalkyl, or C1-C8 alkyl; or D and A together
are
heteroaryl; and each of R a, R b, R b', R c, R c', R d, and R d',
independently, is H, C5-C8
cycloalkenyl, C5-C8 heterocycloalkenyl, aryl, or heteroaryl.
19. The compound of claim 18, wherein each of ~X1-, ~X2-, ~X3-, and ~X4-
, independently, is -C=, -CR a-, or -N=; each of R1 and R2, independently, is
H, C1-C8
alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C1-C6 alkoxy, aryloxy,
heteroaryloxy, or C1-
C6 alkylthio; or R1 and R2 together are C5-C8 heterocycloalkyl; each of R5,
R6, R7, and
R8, independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8
heterocycloalkyl, OH, C1-C6 alkoxy, aryloxy, heteroaryloxy, C1-C6 alkylthio,
arylthio,
halogen, or deleted; or R6 and R7 together are C5-C7 cycloalkyl or C5-C7
heterocycloalkyl; provided that if R5 is deleted, ~X1- is -N=; if R6 is
deleted, ~X2- is -
N=; if R7 is deleted, ~X3- is -N=; and if R8 is deleted, ~X4- is -N=; A is C1-
C12 alkyl
optionally containing 1-6 heteroatoms, C2-C12 alkenyl optionally containing 1-
6
heteroatoms, C2-C12 alkynyl optionally containing 1-6 heteroatoms, aryl, C1-
C10
alkylsulfonyl, arylsulfonyl, C1-C10 alkylcarbonyl containing 1-6 heteroatoms,
C2-C20
alkylaryl optionally containing 1-6 heteroatoms, or C2-C20 arylalkyl
optionally
containing 1-6 heteroatoms; D is H, aryl, heteroaryl, C3-C8 heterocycloalkyl,
or C1-C8
alkyl; and each of R a, R b, R b', R c, R c', R d, and R d', independently, is
H, aryl, or
heteroaryl.
67



20. The method of claim 19, wherein A is C1-C12 alkyl, arylsulfonyl, C1-
C10 alkylcarbonyl containing 1-6 heteroatoms, C2-C20 arylalkyl, or A and B
together
are heteroaryl.
21. The method of claim 20, wherein each of ~X1-, ~X2-, ~X3-, and ~X4-,
independently, is -C=; each of R1 and R2, independently, is H or C1-C8 alkyl;
each of
R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C1-C6 alkoxy, or
halogen; and B
is H or B and A together are heteroaryl.
22. The compound of claim 21, wherein the compound is compound 68 or
compound 70.
23. The compound of claim 19, wherein D is of formula (II),
Image
wherein
each ~ is a single bond or a double bond; provided that if one ~ is a double
bond, its neighboring ~ is not a double bond;
each of ~X1'-, ~X2'-, ~X3'-, and ~X4'-, independently, is -C=, -CR e-, or -N=;
at
most two of ~X1'-, ~X2'-, ~X3'-, and ~X4'- being -N=;
each of R1' and R2', independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, aryl, C1-C6 alkoxy, aryloxy, heteroaryloxy, or C1-C6 alkylthio; or
R1' and R2'
together are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl; and
each of R3', R4', R5', and R6', independently, is H, C1-C8 alkyl, C2-C8
alkenyl,
C2-C8 alkynyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-
C6 alkylthio, arylthio, or halogen; or R4' and R5' together are C5-C7
heterocycloalkyl
in which R e is H, aryl, or heteroaryl.
24. The compound of claim 23, wherein A is C1-C12 alkyl.
68



25. The compound of claim 23, wherein A is C1-C12 alkyl containing 1-6
heteroatoms and optionally substituted with sulfonyl, C1-C6 alkylsulfonyl,
arylsulfonyl, or heteroarylsulfonyl.
26. The compound of claim 23, wherein A is C2-C20 alkylaryl optionally
containing 1-6 heteroatoms.
27. The compound of claim 23, wherein A is aryl, or A and B together are
heteroaryl.
28. The compound of claim 24, wherein each of ~X1-, ~X2-, ~X3-, and ~X4-
, independently, is -C=; each of R1 and R2, independently, is H, C1-C8 alkyl,
or aryl;
each of R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C3-C8
heterocycloalkyl,
OH, C1-C6 alkoxy, aryloxy, C1-C6 alkylthio, or halogen; B is H or C1-C8 alkyl;
each of
~X1'-, ~X2'-, ~X3'-, and ~X4'-, independently, is -C=; each of R1' and R2',
independently, is H, C1-C8 alkyl, or aryl; or R1' and R2' together are C5-C8
cycloalkyl;
each of R3', R4', R5', and R6', independently, is H, C1-C8 alkyl, C3-C8
heterocycloalkyl, OH, C1-C6 alkoxy, aryloxy, C1-C6 alkylthio, or halogen.
29. The compound of claim 28, wherein the compound is one of the
compounds 1-3, 5, 11-12, 19, 23, 30, and 53-55.
30. The compound of claim 25, wherein each of ~X1-, ~X2-, ~X3-, and ~X4-
, independently, is -C=; each of R1 and R2, independently, is H or C1-C8
alkyl; each of
R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C1-C6 alkoxy, aryloxy,
C1-C6
alkylthio, or halogen; B is H; each of ~X1'-, ~X2'-, ~X3'-, and ~X4'-,
independently, is
-C=; each of R1' and R2', independently, is H or C1-C8 alkyl; or R1' and R2'
together
are C5-C8 cycloalkyl; each of R3', R4', R5', and R6', independently, is H, C1-
C8 alkyl,
C1-C6 alkoxy, aryloxy, C1-C6 alkylthio, or halogen.
31. The compound of claim 30, wherein the compound is one of
compounds 31, 41-44, and 51.
69




32. The compound of claim 26, wherein each of ~X1-, ~X2-, ~X3-, and ~X4-
, independently, is -C=; each of R1 and R2, independently, is H or C1-C8
alkyl; each of
R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C1-C6 alkoxy, aryloxy,
or
halogen; B is H; each of ~X1'-, ~X2'-, ~X3'-, and ~X4'-, independently, is -
C=; each of
R1' and R2', independently, is H or C1-C8 alkyl; each of R3', R4', R5', and
R6',
independently, is H, C1-C8 alkyl, C1-C6 alkoxy, aryloxy, or halogen.
33. The compound of claim 32, wherein the compound is one of
compounds 38 and 59-63.
34. The compound of claim 27, wherein each of ~X1-, ~X2-, ~X3-, and ~X4-
, independently, is -C=; each of R1 and R2, independently, is H or C1-C8
alkyl; each of
R5, R6, R7, and R8, independently, is H or C1-C8 alkyl; B is H; or B and A
together are
heteroaryl; each of ~X1'-, ~X2'-, ~X3'-, and ~X4'-, independently, is -C=;
each of R1'
and R2', independently, is H or C1-C8 alkyl; each of R3', R4', R5', and R6',
independently, is H or C1-C8 alkyl.
35. The compound of claim 34, wherein the compound is compound 36.
36. A compound of formula (I):
Image
wherein
each ~ is a single bond or a double bond; provided that if one ~ is a double
bond, its neighboring ~ is not a double bond;
70



each of ~X1-, ~X2-, ~X3-, and ~X4-, independently, is -C=, -CR a-, -N=, -N-, -
S-,
-O-, or a single bond; at most one of ~X1-, ~X2-, ~X3-, and ~X4- being a
single bond
and at most two of ~X1-, ~X2-, ~X3-, and ~X4- being -N=, -N-, -S-, or -O-;
each of R1 and R2, independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, C1-C6 alkylamino, C1-C12 dialkylamino, arylamino,
diarylamino, -C(O)-NR b R b', -OC(O)-R b, -C(O)-R b, or halogen; or R1 and R2
together are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl;
each of R3 and R4, independently, is H or -A-N(B)-D; at most one of R3 and
R4 being H; and
each of R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C2-C8 alkenyl,
C2-
C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-
C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, NO2, CN, C1-C6 alkylamino, C1-C12 dialkylamino,
arylamino,
diarylamino, -C(O)-NR c R c', -C(O)-OR c, -OC(O)-R c, -C(O)-R c, or deleted;
or R5 and
R6 together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R6 and R7
together are
C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R7 and R8 together are C5-C7
cycloalkyl or C5-C7 heterocycloalkyl; provided that if R5 is deleted, ~X1- is -
N=, -S-, -
O-, or a single bond; if R6 is deleted, ~X2- is -N=, -S-, -O-, or a single
bond; if R7 is
deleted, ~X3- is -N=, -S-, -O-, or a single bond; and if R8 is deleted, ~X4-
is -N=, -
S-, -O-, or a single bond; and further provided that not all of R5, R6, R7,
and R8 are H;
in which A is C1-C12 alkyl optionally containing 1-6 heteroatoms, C2-C12
alkenyl
optionally containing 1-6 heteroatoms, C2-C12 alkynyl optionally containing 1-
6
heteroatoms, aryl, heteroaryl, C1-C10 alkylsulfonyl, arylsulfonyl, C1-C10
alkylcarbonyl
containing 1-6 heteroatoms, C2-C20 alkylaryl optionally containing 1-6
heteroatoms,
C2-C20 arylalkyl optionally containing 1-6 heteroatoms, C2-C20 alkylheteroaryl
containing 1-6 heteroatoms, or C2-C20 heteroarylalkyl containing 1-6
heteroatoms;
B is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8
cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8 heterocycloalkenyl, aryl, or
heteroaryl; or
B and A together are heteroaryl; and D is H, aryl, heteroaryl, C1-C8 alkyl, C2-
C8
alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8
heterocycloalkyl,

71


C5-C8 heterocycloalkenyl, -C(O)-R d, -SO2-R d, -C(S)-R d, -C(O)-NR d R d', -
C(O)-
OR d, -OC(O)-R d, -C(O)-SR d, or -SC(O)-R d; or D and A together are
heteroaryl;
each of R a, R b, R b', R c, R c', R d, and R d', independently, being H, C1-
C8 alkyl, C2-C8
alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8
heterocycloalkyl,
C5-C8 heterocycloalkenyl, aryl, or heteroaryl; or R d and R d' together being
C5-C7
heterocycloalkyl;
or a salt thereof.
37. The compound of claim 36, wherein D is of formula (II),
Image
wherein
each ~ is a single bond or a double bond; provided that if one ~ is a double
bond, its neighboring ~ is not a double bond;
each of ~X1'-, ~X2'-, ~X3'-, and ~X4'-, independently, is -C=, -CR e-, -N=, -N-
,
-S-, -O-, or a single bond; at most one of ~X1'-, ~X2'-, ~X3'-, and ~X4'-,
being a
single bond, and at most two of ~X1'-, ~X2'-, ~X3'-, and ~X4'-, being -N=, -N-
, -S-, or
-O-;
each of R1' and R2', independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, C1-C6 alkylamino, C1-C12 dialkylamino, arylamino,
diarylamino, -C(O)-NR f R f', -OC(O)-R f, -C(O)-R f, or halogen; or R1' and
R2'
together are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl;
each of R3', R4', R5', and R6', independently, is H, C1-C8 alkyl, C2-C8
alkenyl,
C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl,
C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, NO2, CN, C1-C6 alkylamino, C1-C12 dialkylamino,
arylamino,
diarylamino, -C(O)-NR g R g', -OC(O)-R g, -C(O)-R g, or deleted; or R3' and
R4' together
72


are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R4' and R5' together are C5-
C7
cycloalkyl or C5-C7 heterocycloalkyl; or R5' and R6' together are C5-C7
cycloalkyl or
C5-C7 heterocycloalkyl; provided that if R3' is deleted, =X1'- is -N=, -S-, -O-
, or a
single bond; if R4' is deleted, =X2'- is -N=, -S-, -O-, or a single bond; if
R5' is deleted,
=X3'- is -N=, -S-, -O-, or a single bond; if R6' is deleted, =X4'- is -N=, -S-
, -O-, or a
single bond; and further provided that not all of R3', R4', R5', and R6' are
H;
in which each of R e, R f, R f', R g, and R g', independently, being H, C1-C8
alkyl, C2-C8
alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8
heterocycloalkyl,
C5-C8 heterocycloalkenyl, aryl, or heteroaryl.

38. ~The compound of claim 36, wherein each of =X1-, =X2-, =X3-, and =X4-
, independently, is -C=, -CR a , -N=, -N-, -S-, or a single bond; each of R1
and R2,
independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8
heterocycloalkyl, aryl, heteroaryl, C1-C6 alkoxy, aryloxy, heteroaryloxy, C1-
C6
alkylthio, arylamino, diarylamino, -C(O)-NR b R b', or -C(O)-R b; or R1 and R2
together
are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl; each of R5, R6, R7, and R8,
independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8
cycloalkyl, C5-
C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8 heterocycloalkenyl, OH, C1-C6
alkoxy, aryloxy, heteroaryloxy, C1-C6 alkylthio, arylthio, NO2, -C(O)-NR c R
c', -C(O)-
R c, or deleted; or R6 and R7 together are C5-C7 cycloalkyl or C5-C7
heterocycloalkyl;
provided that if R5 is deleted, =X1- is -N=, -S-, or a single bond; if R6 is
deleted, =X2-
is -N=, -S-, or a single bond; if R7 is deleted, =X3- is -N=, -S-, or a single
bond; and
if R8 is deleted, =X4- is -N=, -S-, or a single bond; B is H, C1-C8 alkyl, C2-
C8 alkenyl,
C2-C8 alkynyl, aryl, or heteroaryl; or B and A together are heteroaryl; D is
H, aryl,
heteroaryl, C1-C8 alkyl, C3-C8 heterocycloalkyl, or -C(O)-R d; or D and A
together are
heteroaryl; and each of R a, R b, R b', R c, R c', R d, and R d',
independently, is H, C5-C8
cycloalkenyl, C5-C8 heterocycloalkenyl, aryl, or heteroaryl.

39. ~The compound of claim 38, wherein each of =X1-, =X2-, =X3-, and =X4-
independently, is -C=, -CR a-, or -N=; each of R1 and R2, independently, is H,
C1-C8
alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C1-C6 alkoxy, aryloxy,
heteroaryloxy, or C1-~
C6 alkylthio; or R1 and R2 together are C5-C8 cycloalkyl or C5-C8
heterocycloalkyl;~~~

73




each of R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C2-C8 alkenyl,
C2-C8
alkynyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy, aryloxy, heteroaryloxy, C1-
C6
alkylthio, arylthio, or deleted; or R6 and R7 together are C5-C7 cycloalkyl or
C5-C7
heterocycloalkyl; provided that if R5 is deleted, =X1- is -N=; if R6 is
deleted, =X2- is -
N=; if R7 is deleted, =X3- is -N=; and if R8 is deleted, =X4- is -N=; A is C1-
C12
alkyl optionally containing 1-6 heteroatoms, C2-C12 alkenyl optionally
containing 1-6
heteroatoms, C2-C12 alkynyl optionally containing 1-6 heteroatoms, aryl, C1-
C10
alkylsulfonyl, arylsulfonyl, C1-C10 alkylcarbonyl containing 1-6 heteroatoms,
C2-C20
alkylaryl optionally containing 1-6 heteroatoms, or C2-C20 arylalkyl
optionally
containing 1-6 heteroatoms; D is H, aryl, heteroaryl, C1-C8 alkyl, C3-C8
heterocycloalkyl, or -C(O)-R d; and each of R a, R b, R b', R c, R c', R d,
and R d',
independently, is H, aryl, or heteroaryl.

40. The method of claim 39, wherein A is C1-C12 alkyl.

41. The method of claim 40, wherein each of =X1-, =X2-, =X3-, and =X4-,
independently, is -C=; R1 and R2 together are C5-C8 cycloalkyl; each of R5,
R6, R7,
and R8, independently, is H or C1-C8 alkyl; B is H; and D is H, heteroaryl, or
-C(O)-
R d.
42. The compound of claim 41, wherein the compound is compound 72 or
compound 73.

43. The compound of claim 39, wherein D is of formula (II),
Image
wherein
each Image is a single bond or a double bond; provided that if one Image is a
double
bond, its neighboring Image is not a double bond;

74



each of =X1'-, =X2'-, =X3'-, and =X4'-, independently, is -C=, -CR c-, or -N=;
at
most two of =X1'-, =X2'-, =X3'-, and =X4'- being -N=;
each of R1' and R2', independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, aryl, C1-C6 alkoxy, aryloxy, heteroaryloxy, or C1-C6 alkylthio; or
R1' and R2'
together are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl; and
each of R3', R4', R5', and R6', independently, is H, C1-C8 alkyl, C2-C8
alkenyl,
C2-C8 alkynyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-
C6 alkylthio, or arylthio; or R4' and R5' together are C5-C7 cycloalkyl or C5-
C7
heterocycloalkyl
in which R c is H, aryl, or heteroaryl.

44. The compound of claim 43, wherein A is C1-C12 alkyl.

45. The compound of claim 43, wherein A is C1-C12 alkyl containing 1-6
heteroatoms and optionally substituted with sulfonyl, C1-C6 alkylsulfonyl,
arylsulfonyl, or heteroarylsulfonyl.

46. The compound of claim 44, wherein each of =X1-, =X2-, =X3-, and =X4-
independently, is -C=; R1 and R2 together are C5-C8 cycloalkyl; each of R5,
R6, R7,
and R8, independently, is H, C1-C8 alkyl, C1-C6 alkoxy, or halogen; B is H;
each of=
X1'-, =X2'-, =X3'-, and =X4'-, independently, is -C=; each of R1' and R2',
independently, is H or C1-C8 alkyl; or R1' and R2' together are C5-C8
cycloalkyl; each
of R3', R4', R5', and R6', independently, is H, C1-C8 alkyl, or C1-C6 alkoxy.

47. The compound of claim 46, wherein the compound is one of
compounds 25-28 and 57-58.

48. The compound of claim 45, wherein each of =X1-, =X2-, =X3-, and =X4-
independently, is -C=; R1 and R2 together are C5-C8 cycloalkyl; each of R5,
R6, R7,
and R8, independently, is H or C1-C8 alkyl; B is H; each of =X1'-, =X2'-, =X3'-
, and =



X4'-, independently, is -C=; R1' and R2' together are C5-C8 cycloalkyl; each
of R3',
R4', R5', and R6', independently, is H or C1-C8 alkyl.

49. A pharmaceutical composition comprising a compound of formula (I):

Image

wherein
each Image is a single bond or a double bond; provided that if one Image is a
double
bond, its neighboring Image is not a double bond;
each of =X1-, =X2-, =X3-, and =X4-, independently, is -C=, -CR a-, -N=, -N-, -
S-,
-O-, or a single bond; at most one of =X1-, =X2-, =X3-, and =X4- being a
single bond
and at most two of =X1-, =X2-, =X3-, and =X4- being -N=, -N-, -S-, or -O-;
each of R1 and R2, independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, C1-C6 alkylamino, C1-C12 dialkylamino, arylamino,
diarylamino, -C(O)-NR b R b', -C(O)-OR b, -OC(O)-R b, -C(O)-R b, or halogen;
or R1
and R2 together are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl;
each of R3 and R4, independently, is H or -A-N(B)-D; and
each of R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C2-C8 alkenyl,
C2-
C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-
C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, NO2, CN, C1-C6 alkylamino, C1-C12 dialkylamino,
arylamino,
diarylamino, -C(O)-NR c R c', -C(O)-OR c, -OC(O)-R c, -C(O)-R c, halogen, or
deleted; or
R5 and R6 together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R6 and
R7
together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R7 and R8 together
are C5-
C7 cycloalkyl or C5-C7 heterocycloalkyl; provided that if R5 is deleted, =X1-
is -N=,
S-, -O-, or a single bond; if R6 is deleted, =X2- is -N=, -S-, -O-, or a
single bond; if R~

76


is deleted, =X3- is -N=, -S-, -O-, or a single bond; and if R8 is deleted, =X4-
is -N=, -S-
-O-, or a single bond;
in which A is C1-C12 alkyl optionally containing 1-6 heteroatoms, C2-C12
alkenyl
optionally containing 1-6 heteroatoms, C2-C12 alkynyl optionally containing 1-
6
heteroatoms, aryl, heteroaryl, C1-C10 alkylsulfonyl, arylsulfonyl, C1-C10
alkylcarbonyl
containing 1-6 heteroatoms, C2-C20 alkylaryl optionally containing 1-6
heteroatoms,
C2-C20 arylalkyl optionally containing 1-6 heteroatoms, C2-C20 alkylheteroaryl
containing 1-6 heteroatoms, or C2-C20 heteroarylalkyl containing 1-6
heteroatoms;
B is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8
cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8 heterocycloalkenyl, aryl, or
heteroaryl; or
B and A together are C5-C8 heterocycloalkyl or heteroaryl; and D is H, aryl,
heteroaryl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8
cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8 heterocycloalkenyl, -C(O)-R d, -
SO2-R d, -
C(S)-R d, -C(O)-NR d R d', -C(O)-OR d, -OC(O)-R d, -C(O)-SR d, or -SC(O)-R d;
or D
and A together are C5-C7 heterocycloalkyl or heteroaryl; each of R a, R b, R
b', R c, R c',
R d, and R d', independently, being H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, C3-C8
cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8
heterocycloalkenyl,
aryl, or heteroaryl; or R d and R d' together being C5-C7 heterocycloalkyl; or
a salt
thereof; and
a pharmaceutically acceptable carrier.

50. The composition of claim 49, wherein D is of formula (II),

Image

wherein
each Image is a single bond or a double bond; provided that if one Image is a
double
bond, its neighboring Image is not a double bond;
each of =X1'-, =X2'-, =X3'-, and =X4'-, independently, is -C=, -CR e-, -N=, -N-
,
-S-, -O-, or a single bond; at most one of =X1'-, =X2'-, =X3'-, and =X4'-,
being a

77


single bond, and at most two of =X1'-, =X2'-, =X3'-, and =X4'-, being -N=, -N-
, -S-, or
-O-;
each of R1' and R2', independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, C1-C6 alkylamino, C1-C12 dialkylamino, arylamino,
diarylamino, -C(O)-NR f R f', -C(O)-OR f, -OC(O)-R f, -C(O)-R f, or halogen;
or R1' and
R2' together are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl;
each of R3', R4', R5', and R7', independently, is H, C1-C8 alkyl, C2-C8
alkenyl,
C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 heterocycloalkyl,
C5-C8
heterocycloalkenyl, aryl, heteroaryl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-C6
alkylthio, arylthio, NH2, NO2, CN, C1-C6 alkylamino, C1-C12 dialkylamino,
arylamino,
diarylamino, -C(O)-NR g R g', -C(O)-OR g, -OC(O)-R g, -C(O)-R g, halogen, or
deleted;
or R3' and R4' together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R4'
and R5'
together are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; or R5' and R6'
together are
C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; provided that if R3' is deleted,
=X1'- is -
N=, -S-, -O-, or a single bond; if R4' is deleted, =X2'- is -N=, -S-, -O-, or
a single
bond; if R5' is deleted, =X3'- is -N=, -S-, -O-, or a single bond; and if R6'
is deleted, =
X4'- is -N=, -S-, -O-, or a single bond;
in which each of R e, R f, R f', R g, and R g', independently, being H, C1-C8
alkyl, C2-C8
alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8
heterocycloalkyl,
C5-C8 heterocycloalkenyl, aryl, or heteroaryl.

51. The composition of claim 49, wherein each of =X1-, =X2-, =X3-, and =
X4-, independently, is -C=, -CR a-, -N=, -N-, -S-, or a single bond; each of
R1 and R2,
independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8
heterocycloalkyl, aryl, heteroaryl, C1-C6 alkoxy, aryloxy, heteroaryloxy, C1-
C6
alkylthio, arylamino, diarylamino, -C(O)-NR b R b', or -C(O)-R b; or R1 and R2
together
are C5-C7 cycloalkyl or C5-C7 heterocycloalkyl; each of R5, R6, R7, and R8,
independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8
cycloalkyl, C5-
C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-C8 heterocycloalkenyl, OH, C1-C6
alkoxy, aryloxy, heteroaryloxy, C1-C6 alkylthio, arylthio, NO2, -C(O)-NR c R
c', -C(O)-

78



R c, halogen, or deleted; or R6 and R7 together are C5-C7 cycloalkyl or C5-C7
heterocycloalkyl; provided that if R5 is deleted, =X1- is -N=, -S-, or a
single bond; if
R6 is deleted, =X2- is -N=, -S-, or a single bond; if R7 is deleted, =X3- is -
N=, -S-, or
a single bond; and if R8 is deleted, =X4- is -N=, -S-, or a single bond; B is
H, C1-C8
alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, or heteroaryl; or B and A together
are C5-C7
heterocycloalkyl or heteroaryl; D is H, aryl, heteroaryl, C1-C8 alkyl, C3-C8
heterocycloalkyl, or -C(O)-R d; or D and A together are C5-C7 heterocycloalkyl
or
heteroaryl; and each of R a, R b, R b', R c, R c', R d, and R a',
independently, being H, C5-
C8 cycloalkenyl, C5-C8 heterocycloalkenyl, aryl, or heteroaryl.

52. The composition of claim 51, wherein each of =X1-, =X2-, =X3-, and =
X4-, independently, is -C=, -CR a-, or -N=; each of R1 and R2, independently,
is H, C1-
C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C1-C6 alkoxy, aryloxy,
heteroaryloxy, or
C1-C6 alkylthio; or R1 and R2 together are C5-C8 cycloalkyl or C5-C8
heterocycloalkyl;
each of R5, R6, R6, and R8, independently, is H, C1-C8 alkyl, C2-C8 alkenyl,
C2-C8
alkynyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy, aryloxy, heteroaryloxy, C1-
C6
alkylthio, arylthio, halogen, or deleted; or R6 and R7 together are C5-C7
cycloalkyl or
C5-C7 heterocycloalkyl; provided that if R5 is deleted, =X1- is -N=; if R6 is
deleted, =
X2- is -N=; if R7 is deleted, =X3- is -N=; and if R8 is deleted, =X4- is -N=;
A is
C1-C12 alkyl optionally containing 1-6 heteroatoms, C2-C12 alkenyl optionally
containing 1-6 heteroatoms, C2-C12 alkynyl optionally containing 1-6
heteroatoms,
aryl, C1-C10 alkylsulfonyl, arylsulfonyl, C1-C10 alkylcarbonyl containing 1-6
heteroatoms, C2-C20 alkylaryl optionally containing 1-6 heteroatoms, or C2-C2
arylalkyl optionally containing 1-6 heteroatoms; D is H, aryl, heteroaryl, C1-
C8 alkyl,
C3-C8 heterocycloalkyl, or -C(O)-R d; and each of R a, R b, R b', R c, R c', R
d,
and R a', independently, being H, aryl, or heteroaryl.

53. The method of claim 52, wherein A is C1-C12 alkyl, arylsulfonyl, C1-
C10 alkylcarbonyl containing 1-6 heteroatoms, C2-C20 arylalkyl, or A and B
together
are heteroaryl.

79



54. The method of claim 53, wherein each of =X1-, =X2-, =X3-, and =X4-,
independently, is -C=; each of R1 and R2, independently, is H or C1-C8 alkyl;
or R1
and R2 together are C5-C8 cycloalkyl; each of R5, R6, R7, and R8,
independently, is H,
C1-C8 alkyl, C1-C6 alkoxy, or halogen; and B is H or B and A together are
heteroaryl.

55. The composition of claim 52, wherein D is of formula (II),

Image

wherein
each Image is a single bond or a double bond; provided that if one Image is a
double
bond, its neighboring Image is not a double bond;
each of =X1'-, =X2'-, =X3'-, and =X4'-, independently, is -C=, -CR e-, or -N=;
at
most two of =X1'-, =X2'-, =X3'-, and =X4'- being -N=;
each of R1' and R2', independently, is H, C1-C8 alkyl, C2-C8 alkenyl, C2-C8
alkynyl, aryl, C1-C6 alkoxy, aryloxy, heteroaryloxy, or C1-C6 alkylthio; or
R1' and R2'
together are C5-C8 cycloalkyl or C5-C8 heterocycloalkyl; and
each of R3', R4', R5', and R6', independently, is H, C1-C8 alkyl, C2-C8
alkenyl,
C2-C8 alkynyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy, aryloxy,
heteroaryloxy, C1-
C6 alkylthio, arylthio, or halogen; or R4' and R5' together are C5-C7
cycloalkyl or C5-
C7 heterocycloalkyl
in which R e is H, aryl, or heteroaryl.

56. The composition of claim 55, wherein A is C1-C12 alkyl.

57. The composition of claim 55, wherein A is C1-C12 alkyl containing 1-6
heteroatoms and optionally substituted with sulfonyl, C1-C6 alkylsulfonyl,
arylsulfonyl, or heteroarylsulfonyl.

80



58. The composition of claim 55, wherein A is C2-C20 alkylaryl optionally
containing 1-6 heteroatoms.

59. The composition of claim 55, wherein A is aryl, or A and B together
are heteroaryl.

60. The composition of claim 56, wherein each of =X1-, =X2-, =X3-, and =
X4-, independently, is -C=; each of R1 and R2, independently, is H, C1-C8
alkyl, or
aryl; or R1 and R2 together are C5-C8 cycloalkyl; each of R5, R6, R7, and R8,
independently, is H, C1-C8 alkyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy,
aryloxy,
C1-C6 alkylthio, or halogen; B is H or C1-C8 alkyl; each of =X1'-, =X2'-, =X3'-
, and =
X4'-, independently, is -C=; each of R1' and R2', independently, is H, C1-C8
alkyl, or
aryl; or R1' and R2' together are C5-C8 cycloalkyl; each of R3', R4', R5', and
R6',
independently, is H, C1-C8 alkyl, C3-C8 heterocycloalkyl, OH, C1-C6 alkoxy,
aryloxy,
C1-C6 alkylthio, or halogen.

61. The composition of claim 57, wherein each of =X1-, =X2-, =X3-, and =
X4-, independently, is -C=; each of R1 and R2, independently, is H or C1-C8
alkyl; or
R1 and R2 together are C5-C8 cycloalkyl; each of R5, R6, R7, and R8,
independently, is
H, C1-C8 alkyl, C1-C6 alkoxy, aryloxy, C1-C6 alkylthio, or halogen; B is H;
each of =
X1'-, =X2'-, =X3'-, and =X4'-, independently, is -C=; each of R1' and R2',
independently, is H or C1-C8 alkyl; or R1' and R2' together are C5-C8
cycloalkyl; each
of R3', R4', R5', and R6', independently, is H, C1-C8 alkyl, C1-C6 alkoxy,
aryloxy, C1-
C6 alkylthio, or halogen.

62. The composition of claim 58, wherein each of =X1-, =X2-, =X3-, and =
X4-, independently, is -C=; each of R1 and R2, independently, is H or C1-C8
alkyl;
each of R5, R6, R7, and R8, independently, is H, C1-C8 alkyl, C1-C6 alkoxy,
aryloxy, or
halogen; B is H; each of =X1'-, =X2'-, =X3'-, and =X4'-, independently, is -
C=; each of
R1' and R2', independently, is H or C1-C8 alkyl; each of R3', R4', R5', and
R6',
independently, is H, C1-C8 alkyl, C1-C6 alkoxy, aryloxy, or halogen.

81



63. The composition of claim 59, wherein each of =X1-, =X2-, =X3-, and =
X4-, independently, is -C=; each of R1 and R2, independently, is H or C1-C8
alkyl;
each of R5, R6, R7, and R8, independently, is H or C1-C8 alkyl; B is H; or B
and A
together are heteroaryl; each of =X1'-, =X2'-, =X3'-, and =X4'-,
independently, is -C=;
each of R1' and R2', independently, is H or C1-C8 alkyl; each of R3', R4',
R5', and R6',
independently, is H or C1-C8 alkyl.

82

Description

CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Aminoquinoline Compounds
CROSS REFERENCE TO RELATED APPLICATIONS
Pursuant to 35 USC ~ 119(e), this application claims priority to U.S.
Provisional Application Serial No. 60/462,495, filed April 11, 2003, and U.S.
Provisional Application Serial No. 60/551,750, filed March 9, 2004, the
contents of
which are incorporated herein by reference.
BACKGROUND
Chemokines have been classified into four groups according to their
structures. CXC and CC chemokines, the two large groups, feature the presence
and
absence of an amino acid, respectively, between the first two cysteine
residues in a
~5 conserved four-cysteine motif (Mackay C.R., Nat. Immunol., (2001) 2:95;
Olson et
al., Am. J. Physiol. Regul. Integr. Comp. Physiol., (2002) 283:R7). CXCR3 is
the
first chemokine receptor found to be highly induced by T cell activation
(Loetscher et
al., J. Exp. Med., (1996) 184:963). CXCR3 is expressed on some circulating
blood T
cells, B cells, and natural killer cells (Qin et al., J. Clin. Invest., (1998)
101:746). For
2o example, expression of CXCR3 is induced virtually by all T cells in
synovial fluid of
rheumatoid arthritis and in various inflamed tissues (e.g., ulcerative
colitis, chronic
vaginitis, and sarcoidosis), particularly in perivascular regions. However,
few T cells
in normal lymph nodes are induced to express CXCR3 (Agostini et al., J.
Immunol.,
(1998) 161:6413). Expression and responsiveness of CXCR3 can be markedly
25 increased by T cell activation (Rabin et al., J. Immunol., (1999)
162:3840). CXCR3
is also consistently detected in functional forms on transformed B cells
obtained from
chronic lymphocytic leukemia patients (Trentin et al., J. Clin. Invest.,
(1999)
104:115).
CXCR3 binds to three highly potent, inflammation-inducible, ELR-negative
3o CXC chemokines, i.e., I-TAC, Mig, and IP-10. These three chemokines
chemoattract
and induce calcium influx in activated T cells, tumor-infiltrating
lymphocytes, and
CXCR3-transfected cells (Loetscher et al., Eur. J. Immunol., (1998) 28:3696;
Cole et
al., J. Exp. Med., (1998) 187:2009; Weng et al., J. Biol. Chem., (1998)
273:18288).



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
CXCR3 signaling appears to be an important mechanism for selective homing of
activated/effector cells, which are known to accumulate preferentially at
inflammatory
sites and in many tumors. For example, IP-10 is expressed abundantly at
various
inflammatory sites, particularly those characterized by T cell infiltration,
such as in
tissues affected by delayed type hypersensitivity responses, experimental
autoimmune
o encephalomyelitis, or a transplant undergoing rejection (Qin et al., J.
Clin. Invest.,
(1998) 101:746). CXCR3 ligand-induced recruitment of leukocytes is thought to
be
an essential step in the pathogenesis of tissue-specific autoimmune
inflammatory
diseases, as well as in graft rejection (Hancock et al., J. Exp. Med., (2000)
192:1515).
SUMMARY
~ 5 This invention is based on the discovery that certain aminoquinoline
compounds are effective in treating inflammatory and immune diseases through
their
binding to CXCR3 receptors.
In one aspect, this invention features aminoquinoline compounds of formula
(n or their salts:
20 (I)~
In this formula, each -- is a single bond or a double bond; provided that if
one -- is
a double bond, its neighboring -- is not a double bond; each of =X~-, =XZ-,
=X3-, and
=X4-, independently, is -C=, -CRa , -N=, -N-, -S-, -O-, or a single bond; at
most one of
=X~-, =XZ-, =X3-, and =X4- being a single bond, and at most two of =X,-, =XZ-,
=X3-,
25 and =X4- being -N=, -N-, -S-, or -O-; each of Rt and RZ, independently, is
H, C,-Cg
alkyl, CZ-Cg alkenyl, CZ-C8 alkynyl, C3-Cg cycloalkyl, CS-C8 cycloalkenyl, C3-
C8
heterocycloalkyl, CS-C8 heterocycloalkenyl, aryl, heteroaryl, OH, C,-C6
alkoxy,
aryloxy, heteroaryloxy, C~-C6 alkylthio, arylthio, NH2, C1-C6 alkylamino, C~-
C12
dialkylamino, arylamino, diarylamino, -C(O)-NRbRb', -C(O)-ORb, -OC(O)-Rb, -
C(O)-
3o Rb, or halogen; or RI and RZ together are CS-Cg heterocycloalkyl; each of
R3 and R4,
2



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
independently, is H or -A-N(B)-D; and each of R5, Rb, R~, and Rg,
independently, is
H, C~-C8 alkyl, C2-Cg alkenyl, CZ-C8 alkynyl, C3-Cg cycloalkyl, CS-C8
cycloalkenyl,
C3-Cg heterocycloalkyl, CS-C$ heterocycloalkenyl, aryl, heteroaryl, OH, Cl-C6
alkoxy,
aryloxy, heteroaryloxy, Cl-C6 alkylthio, arylthio, NH2, NO2, CN, C~-C6
alkylamino,
C,-C~2 dialkylamino, arylamino, diarylamino, -C(O)-NR~R~', -C(O)-OR~, -OC(O)-
R~,
~o -C(O)-R~, halogen, or deleted; or RS and R6 together are CS-C~ cycloalkyl
or C5-C~
heterocycloalkyl; or R6 and R~ together are CS-C~ cycloalkyl or CS-C~
heterocycloalkyl; or R~ and R8 together are CS-C~ cycloalkyl or CS-C~
heterocycloalkyl; provided that if RS is deleted, =Xl- is -N=, -S-, -O-, or a
single bond;
if R~ is deleted, =XZ- is -N=, -S-, -O-, or a single bond; if R~ is deleted,
=X3- is -N=, -
~ 5 S-, -O-, or a single bond; and if Rg is deleted, =X4- is -N=, -S-, -O-, or
a single bond.
A is C,-C12 alkyl optionally containing 1-6 heteroatoms, CZ-C12 alkenyl
optionally
containing 1-6 heteroatoms, CZ-C12 alkynyl optionally containing 1-6
heteroatoms,
aryl, heteroaryl, C1-C~o alkylsulfonyl, arylsulfonyl, CI-Clo alkylcarbonyl
containing 1-
6 heteroatoms, CZ-CZO alkylaryl optionally containing 1-6 heteroatoms, CZ-CZo
2o arylalkyl optionally containing 1-6 heteroatoms, CZ-C2o alkylheteroaryl
containing 1-6
heteroatoms, or CZ-CZO heteroarylalkyl containing 1-6 heteroatoms. B is H, C~-
C8
alkyl, CZ-C$ alkenyl, CZ-Cg alkynyl, C3-C8 cycloalkyl, CS-Cg cycloalkenyl, C3-
Cg
heterocycloalkyl, CS-C$ heterocycloalkenyl, aryl, or heteroaryl; or B and A
together
are heteroaryl. D is H, aryl, heteroaryl, C1-Cg alkyl, CZ-C$ alkenyl, CZ-Cg
alkynyl, C3-
25 Cg cycloalkyl, CS-C8 cycloalkenyl, C3-C8 heterocycloalkyl, C5-Cg
heterocycloalkenyl,
-C(O)-Rd, -SOZ-Ra, -C(S)-Rd, -C(O)-NRdRa', -C(O)-ORa, -OC(O)-R~, -C(O)-SRa, or
-SC(O)-Rd; or D and A together are heteroaryl. Each of Ra, Rb, Rb', R~, R~',
Rd, and
Ra', independently, is H, C~-Cg alkyl, CZ-C$ alkenyl, C2-Cg alkynyl, C3-Cg
cycloalkyl,
CS-Cg cycloalkenyl, C3-Cg heterocycloalkyl, CS-Cg heterocycloalkenyl, aryl, or
3o heteroaryl; or Rd and Rd' together being CS-C~ heterocycloalkyl.
Referring to formula (I), a subset of the compounds described above are those
in which D is of formula (II):



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
R4
Rs
(II).
In formula (II), each -- is a single bond or a double bond; provided that if
one -- is
a double bond, its neighboring -- is not a double bond; each of=X1'-, =XZ'-,
=X3'-,
and =X4'-, independently, is -C=, -CRe-, -N=, -N-, -S-, -O-, or a single bond;
at most
one of=X~'-, =XZ'-, =X3'-, and =X4'-, being a single bond, and at most two of
=X~'-, =
o XZ'-, =X3'-, and =X4'-, being -N=, -N-, -S-, or -O-; each of R~' and R2',
independently, is H, C1-Cg alkyl, CZ-Cg alkenyl, CZ-C$ alkynyl, C3-Cg
cycloalkyl, CS-
Cg cycloalkenyl, C3-C$ heterocycloalkyl, CS-Cg heterocycloalkenyl, aryl,
heteroaryl,
OH, C,-C6 alkoxy, aryloxy, heteroaryloxy, C1-C6 alkylthio, arylthio, NHz, C1-
C6
alkylamino, C1-C1z dialkylamino, arylamino, diarylamino, -C(O)-NRfRf', -C(O)-
ORf,
~5 -OC(O)-Rf, -C(O)-Rf, or halogen; or Rl' and RZ' together are CS-C$
cycloalkyl or CS-
Cg heterocycloalkyl; each of R3', R4', RS', and R6', independently, is H, C1-
Cg alkyl,
CZ-C8 alkenyl, C2-C8 alkynyl, C3-C$ cycloalkyl, CS-Cg cycloalkenyl, C3-C$
heterocycloalkyl, CS-Cg heterocycloalkenyl, aryl, heteroaryl, OH, C1-C~
alkoxy,
aryloxy, heteroaryloxy, C1-C6 alkylthio, arylthio, NHZ, NO2, CN, C~-C6
alkylamino,
2o C~-C12 dialkylamino, arylamino, diarylamino, -C(O)-NRgRg', -C(O)-
ORg, -OC(O)-Rg, -C(O)-Rg, halogen, or deleted; or R3' and R4' together are CS-
C~
cycloalkyl or CS-C~ heterocycloalkyl; or R4' and RS' together are CS-C~
cycloalkyl or
CS-C~ heterocycloalkyl; or RS' and R6'together are CS-C~ cycloalkyl or CS-C~
heterocycloalkyl; provided that if R3'is deleted, =X1'- is -N=, -S-, -O-, or a
single
25 bond; if R4' is deleted, =XZ'- is -N=, -S-, -O-, or a single bond; if RS'
is deleted, =X3'-
is -N=, -S-, -O-, or a single bond; and if R6' is deleted, =X4'- is -N=, -S-, -
O-, or a
single bond. Each of Re, Rf, Rf', Rg, and Rg', independently, being H, C~-Cg
alkyl, CZ-
Cg alkenyl, CZ-Cg alkynyl, C3-C8 cycloalkyl, CS-Cg cycloalkenyl, C3-C8
heterocycloalkyl, CS-Cg heterocycloalkenyl, aryl, or heteroaryl. Referring to
formula
30 (n, another subset of the compounds described above are those in which A is
C,-C~2
alkyl; C,-C,Z alkyl containing 1-6 heteroatoms and optionally substituted with
4



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
sulfonyl, C~-C6 alkylsulfonyl, arylsulfonyl, or heteroarylsulfonyl; CZ-CZO
alkylaryl
optionally containing 1-6 heteroatoms; or aryl; or A and B together are
heteroaryl.
The term "alkyl" refers to a saturated, linear or branched hydrocarbon moiety,
such as -CH3, -CHZ-, or branched -C3H~. The term "alkenyl" refers to a linear
or
branched, non-aromatic hydrocarbon moiety having at least one double bond,
such as
o -CH=CHZ or -CH=CH-. The term "alkynyl" refers to a linear or branched, non-
aromatic hydrocarbon moiety having at least one triple bond, such as -C---CH
or -
C---C-. The term "cycloalkyl" refers to a saturated cyclic hydrocarbon moiety,
such as
cyclohexyl. The term "cycloalkenyl" refers to a non-aromatic cyclic
hydrocarbon
moiety having at least one double bond in the ring, such as 2-cyclopentenyl.
The term
~ 5 "heterocycloalkyl" refers to a saturated non-aromatic cyclic moiety having
at least
one ring heteroatom (e.g., O, N, and S), such as 4-tetrahydropyranyl. The term
"heterocycloalkenyl" refers to a non-aromatic cyclic moiety having at least
one ring
heteroatom and at least one double bond in the ring, such as 3,4-dihydropyran-
4-yl.
The term "alkoxy" refers to a linear or branched, saturated or unsaturated,
non-
2o aromatic hydrocarbon moiety containing an oxygen radical, such as -OCH3 or -

OCH=CZHS. The term "aryloxy" refers to a moiety having at least one aromatic
ring
and an oxygen radical bonded to the aromatic ring, such as phenoxy. The term
"heteroaryloxy" refers to a moiety having at least one aromatic ring that
contains at
least one ring heteroatom and an oxygen radical bonded to the aromatic ring,
such as
25 4-pyrindinoxy. The term "aryl" refers to a hydrocarbon moiety having one or
more
aromatic rings. Examples of an aryl moiety include phenyl, phenylene,
naphthyl,
naphthylene, pyrenyl, anthryl, and phenanthryl. The term "heteroaryl" refers
to a
moiety having one or more aromatic rings that contain at least one heteroatom.
Examples of a heteroaryl moiety include furyl, furylene, fluorenyl, pyrrolyl,
thienyl,
30 oxazolyl, imidazolyl, thiazolyl, pyridyl, pyrimidinyl, quinazolinyl,
quinolyl,
isoquinolyl and indolyl. The term "alkylaryl" refers to an aryl moiety
substituted with
/ \
/ \
unsubstituted or substituted alk 1 such as '~"2~ or . The term
Y> >
"alkylheteroaryl" refers to a heteroaryl moiety substituted with unsubstituted
or



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
substituted alkyl. The terms "arylalkyl" and "heteroarylalkyl" respectively
refer to an
alkyl moiety substituted with unsubstituted or substituted aryl and an alkyl
moiety
substituted with unsubstituted or substituted heteroaryl, such as benzyl or
pyridinylmethyl. Alkylaryl and arylalkyl may optionally contain 1-6
heteroatoms.
Alkylheteroaryl and heteroarylalkyl contain 1-6 heteroatoms.
o Alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl,
heterocycloalkenyl, alkoxy, aryloxy, heteroaryloxy, aryl, and heteroaryl
mentioned
herein include both substituted and unsubstituted moieties. Examples of
substituents
for cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryloxy,
heteroaryloxy, aryl, and heteroaryl include C~-Coo alkyl, Cz-C1o alkenyl, Cz-
Coo
~5 alkynyl, C3-Cg cycloalkyl, CS-C$ cycloalkenyl, CI-Coo alkoxy, aryl,
aryloxy,
heteroaryl, heteroaryloxy, C,-Coo alkylsulfonyl, arylsulfonyl,
heteroarylsulfonyl,
amino, C~-Coo alkylamino, C~-Czo dialkylamino, arylamino, diarylamino, Cl-Clo
alkylimino, arylimino, amido, carbamoyl, thioamido, thiocarbamoyl, hydroxyl,
halogen, thio, Ci-Clo alkylthio, arylthio, cyano, nitro, acyl, acyloxy,
carboxyl, and
2o carboxylic ester. Examples of substituents for alkyl, alkenyl, alkynyl, and
alkoxy
include all of the above substitutents except C1-Clo alkyl, Cz-C,o alkenyl,
and Cz-Coo
alkynyl. Cycloalkyl, cycloalkenyl, heterocycloalkyl heterocycloalkenyl, aryl,
and
heteroaryl also include fused groups.
In another aspect, this invention features aminoquinoline compounds of
25 formula (I) shown above except that each of R~ and Rz, independently, is H,
C~-C8
alkyl, Cz-Cg alkenyl, Cz-Cg alkynyl, C3-Cg cycloalkyl, CS-C8 cycloalkenyl, C3-
Cg
heterocycloalkyl, CS-Cg heterocycloalkenyl, aryl, heteroaryl, OH, C~-C~
alkoxy,
aryloxy, heteroaryloxy, C~-C6 alkylthio, arylthio, NHz, C1-C6 alkylamino, C1-
Clz
dialkylamino, arylamino, diarylamino, -C(O)-NRbRb', -OC(O)-Rb, -C(O)-Rb, or
3o halogen; or R~ and Rz together are CS-C8 cycloalkyl or CS-Cg
heterocycloalkyl; each
of R5, R6, R~, and R8, independently, is H, C~-C8 alkyl, Cz-C8 alkenyl, Cz-Cg
alkynyl,
C3-C8 cycloalkyl, CS-C8 cycloalkenyl, C3-C8 heterocycloalkyl, CS-Cg
heterocycloalkenyl, aryl, heteroaryl, OH, C,-C6 alkoxy, aryloxy,
heteroaryloxy, C~-C6
alkylthio, arylthio, NHz, NOz, CN, Cl-C6 alkylamino, Cl-C~z dialkylamino,
arylamino,
35 diarylamino, -C(O)-NR~R~', -C(O)-OR~, -OC(O)-R~, -C(O)-R~, or deleted; or
RS and
R6 together are CS-C~ cycloalkyl or CS-C~ heterocycloalkyl; or R6 and R~
together are
6



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
CS-C~ cycloalkyl or CS-C~ heterocycloalkyl; or R~ and R8 together are CS-C~
cycloalkyl or CS-C~ heterocycloalkyl; provided that if RS is deleted, =XI- is -
N=, -
S-, -O-, or a single bond; if R6 is deleted, =XZ- is -N=, -S-, -O-, or a
single bond; if R~
is deleted, =X3- is -N=, -S-, -O-, or a single bond; and if R8 is deleted, =X4-
is -N=, -S-
-O-, or a single bond; and further provided that not all of R5, R6, R~, and R8
are H;
In still another aspect, this invention features a method for treating an
inflammatory or immune disease. The method includes administering to a subject
in
need of treatment of an effective amount of one or more compounds of formula
(I)
shown above except that each of R~ and R2, independently, is H, CI-Cg alkyl,
CZ-Cg
alkenyl, CZ-Cg alkynyl, C3-Cg cycloalkyl, CS-Cg cycloalkenyl, C3-C8
heterocycloalkyl,
~5 CS-Cg heterocycloalkenyl, aryl, heteroaryl, OH, C~-C6 alkoxy, aryloxy,
heteroaryloxy,
C1-C6 alkylthio, arylthio, NHz, C1-C6 alkylamino, C1-C12 dialkylamino,
arylamino,
diarylamino, -C(O)-NRbRb', -C(O)-ORb, -OC(O)-Rb, -C(O)-Rb, or halogen; or Rl
and
RZ together are CS-C$ cycloalkyl or CS-C8 heterocycloalkyl; each of R5, R6,
R~, and
Rg, independently, is H, C1-Cg alkyl, CZ-Cg alkenyl, CZ-Cg alkynyl, C3-C$
cycloalkyl,
2o CS-C8 cycloalkenyl, C3-C8 heterocycloalkyl, CS-C8 heterocycloalkenyl, aryl,
heteroaryl, OH, C~-C6 alkoxy, aryloxy, heteroaryloxy, C1-C6 alkylthio,
arylthio, NHZ,
NO2, CN, CI-C6 alkylamino, C~-C~Z dialkylamino, arylamino, diarylamino, -C(O)-
NR~R~', -C(O)-ORS, -OC(O)-R~, -C(O)-R~, halogen, or deleted; or RS and R6
together
are CS-C~ cycloalkyl or CS-C~ heterocycloalkyl; or R6 and R~ together are C5-
C~
25 cycloalkyl or CS-C~ heterocycloalkyl; or R~ and Rg together are CS-C~
cycloalkyl or
CS-C~ heterocycloalkyl; provided that if RS is deleted, =X,- is -N=, -S-, -O-,
or a
single bond; if R6 is deleted, =Xz- is -N=, -S-, -O-, or a single bond; if R~
is deleted, =
X3- is -N=, -S-, -O-, or a single bond; and if Rg is deleted, =X4- is -N=, -S-
, -O-, or a
single bond; in which B is H, C1-Cg alkyl, C2-Cg alkenyl, CZ-C8 alkynyl, C3-Cg
3o cycloalkyl, CS-Cg cycloalkenyl, C3-Cg heterocycloalkyl, CS-Cg
heterocycloalkenyl,
aryl, or heteroaryl; or B and A together are CS-C~ heterocycloalkyl or
heteroaryl; and
D is H, aryl, heteroaryl, C,-Cg alkyl, CZ-Cg alkenyl, CZ-C8 alkynyl, C3-C8
cycloalkyl,
CS-Cg cycloalkenyl, C3-Cg heterocycloalkyl, CS-Cg heterocycloalkenyl, -C(O)-
Rd, -SOZ-Ra, -C(S)-Rd, -C(O)-NRdRd', -C(O)-ORd, -OC(O)-Rd, -C(O)-SRd, or -
35 SC(O)-Rd; or D and A together are CS-C~ heterocycloalkyl or heteroaryl.



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
"Treatment" refers to administering one or more aminoquinoline compounds
to a subject, who has an inflammatory or immune disease, a symptom of such a
disease, or a predisposition toward such a disease, with the purpose to confer
a
therapeutic effect, e.g., to cure, relieve, alter, affect, ameliorate, or
prevent the
inflammatory or immune disease, the symptom of it, or the predisposition
toward it.
~o "An effective amount" refers to the amount of one or more active
aminoquinoline
compounds that is required to confer a therapeutic effect on a treated
subject.
An inflammatory disease is characterized by a local or systemic, acute or
chronic inflammation. An immune disease is characterized by a hyper- or hypo-
reaction of the immune system. Examples of inflammatory or immune diseases
~5 include multiple sclerosis, systemic lupus erythematosus, rheumatoid
arthritis,
atherosclerosis, encephalitis, meningitis, hepatitis, nephritis, sepsis,
sarcoidosis,
psoriasis, eczema, uticaria, Type I diabetes, asthma, conjunctivitis, otitis,
allergic
rhinitis, chronic obstructive pulmonary disease, sinusitis, dermatitis,
inflammatory
bowel disease, ulcerative colitis, Crohn's disease, Behcet's syndrome, gout,
cancer,
2o viral infections, bacterial infections, organ transplant conditions, skin
transplant
conditions, graft rejection (including allograft rejection and graft-versus-
host disease),
spondyloarthropathies, scleroderma, vasculitis, and psoriasis (including T-
cell
mediated psoriasis).
A subject in need of treatment of an inflammatory or immune disease can also
25 be concurrently administered with an aminoquinoline compound described
above and
one or more other therapeutic agents at the same time or at different times
during the
period of treatment. Examples of such a therapeutic agent include a steroidal
or a
non-steroidal anti-inflammatory drug, a COX2 inhibitor, a leukotriene receptor
inhibitor, a prostaglandin modulator, a TNF modulator, and an
immunosuppressive
3o agent (e.g., cyclosporine A).
In a further aspect, this invention features a pharmaceutical composition that
contains an effective amount of at least one of the above-mentioned
aminoquinoline
compounds and a pharmaceutically acceptable Garner.
The aminoquinoline compounds described above include the compounds
35 themselves, as well as their salts and their prodrugs, if applicable. A
salt, for
example, can be formed between an anion and a positively charged group (e.g.,



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
amino) on an aminoquinoline compound. Suitable anions include chloride,
bromide,
iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate,
methanesulfonate,
trifluoroacetate, maleate, succinate, fumarate, tartrate, salicylate, lactate,
naphthalenesulfonate, and acetate. Likewise, a salt can also be formed between
a
cation and a negatively charged group (e.g., carboxylate) on an aminoquinoline
1 o compound. Suitable cations include sodium ion, potassium ion, magnesium
ion,
calcium ion, and an ammonium cation such as tetramethylammonium ion. The
aminoquinoline compounds also include those salts containing quaternary
nitrogen
atoms. Examples of prodrugs include esters and other pharmaceutically
acceptable
derivatives, which, upon administration to a subject, are capable of providing
active
~5 aminoquinoline compounds.
Also within the scope of this invention is a composition containing one or
more of the aminoquinoline compounds described above for use in treating an
inflammatory disease or an immune disease, and the use of such a composition
for the
manufacture of a medicament for the just-mentioned treatment.
2o The details of one or more embodiments of the invention are set forth in
the
description below. Other features, objects, and advantages of the invention
will be
apparent from the description and from the claims.
9



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
DETAILED DESCRIPTION
Shown below are exemplary compounds, compounds 1-190, of this invention.
H3 CH3 CH ~
\ CH3 \ CH3 \ \ I H
H N~NH H3 NFi~NH CH3 NFi\~NH
I \ \ ~I
f~ CH C'~.~~CH3 \CH3
3
Compound 1 Compound 2 Compound 3
CHI ~ I CH3 CH3 CH3 CH3
~cH3 N I ~ \ ~ I ~N I
CH3 NH NH ( ~NH NH I ~NH ~''
\ \ ~N
I ~ N H CHs CH3 CH3 CH3
3
Compound 4 Compound 5 Compound 6
CH3 N H3 dCH3 aCH3 CH3
i
N\OH N' I N I I N N
N ~ i I N vw I ~ \ ~\/~NH I
HO N N,
CH3 aCH3 CH3 Hs CI~3
Compound 7 Compound 8 Compound 9
H3
~CH3 CH3 / N \ \ I / I \
I N ~ -~NH \
NF~N I ~ NH ~ I 1 \ NON I I
N
N N I
CH3 CH3 CH3 CHs ~ s
Compound 10 Compound 11 Compound 12
CH3
CH3 I \ H3 S.CH3
I -wNH I
N~NH\ ~ p'~ N ~NH N~~ N NH
N \ I ~N ~ i \ I I N
CH3 \ I O I CH3 CH CH3
3
Compound 13 Compound 14 Compound IS
-CH
H3 S 3 Hs ~CH3 Hs F
N I N ~NH I \ N I N ~NH I N I N ~NH I
w I I N w I I N w I I N
~CH3 CH3 ~CH3 CH3 F CH3
Compound 16 Compound 17 Compound 18
10



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
CHs CI H3 Br Hs CHs
N. I 'w/wN I w N I -w~N I N I N I
I NH I I NH I ~ I N ~ I
N ~N ~N
CI CHs Br CHs CH CHs
3
Compound 19 Compound 20 Compound 21
CHs CHs Hs Br I CHs Hs F / I CHs
N I I N ~NHI I I I N~NH~ ~ I I NH~NH~
~N N / ~ ~ I N I
CHs CHs CHs I / Br CHs CHs I F CHs
Compound 22 Compound 23 Compound 24
CHs
I / I CHs
N
/ N'
I NH~'N I N N I N ~NH~ ~ I \ I I N ~N I ,N
I I
CHs CHs CHs CHs
Compound 25 Compound 26 Compound 27
H CHs -CHs I w ~ CHs
3 /
/ CH~
I N~ ~_N _
CHs i N~NH~ '~ I CHs N NH \ I H3 H N CH~H HsN'H
N~ w O
I
CHs Q CHs CHs
CHs
Compound 28 Compound 29 Compound 30
H3~ Hs
Hs CHs I CHs
N, C'~CHs / N I
I I NhI~S'S~NHI I / C N ~N~CHs I I NH~ I ~N
N I w CHs
CHs CHs N CHs CHs
Compound 31 Compound 32 Compound 33
H CHs Hs
H3 H3
N~ ~ N I / \ NH I / s N ~ N \~ I
NH / N / \ I
CHs I CH ~ CH ~ CHs
CHg CH3 3 3
Compound 34 Compound 35 Compound 36
11



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
CHs
CHs ~ NHS I
S.S ~ w
I NH ~ CHs
N
CHs
Compound 37 compound 38 Compound 39
N O I O.CHs Q
CHs N~'N~NH I ~ CHs NF~NC NH NH~N'~NH
~ ~ ' w CH3
CH CHs ( ~ N CHs ~CH H ~ ~ '
3 3 N CH3CH3N
Compound 40 Compound 41 Compound 42
CHs Br
Qi5 w I CHs
O , O-
NFi~'N~NH NFi~N'~NH N
CH ~ ' ~~CH3 CH' ~ ~ CH ' I \ ~O~O~NH
.l\ ~~J~' s N I
N CH3CH~J ~ tf CH3C~ CH
3
Compound 43 Compound 44 Compound 45
CI 8r
\ \ CHs CHs \
H ~\--,~ ~ NH NH \ ,N CI N ~N~NH
CHs / , ~v ~ / I ~ ~ p ~ CI
CHs ~
ff CH3CH~~
CI Br
Compound 46 Compound 47 Compound 48
Q w I F ~ w I aCHs
N vN~NH ~ O_-~ O:
O ~ ~ ~ NH~N'~NH N ~N~NH
I N H CH~CI ~ w ' w CI CI ~ w ' CI
~~ ~ ~~ I
~CH CH~ \~CH
3 3
Compound 49 Compound 50 Compound 51
'I
O , CHs
NH~N'~NH Nhi~NH N
Hs ~~/~~CHs Hs y~O.CH CHI I N ~N I I '
I J.~~j~~~j 3 3
N N CH3CHs N
CHs
Compound SZ Compound 53 Compound 54
12



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
NFi~NH NFi~NH NH~NH
CHi ~ / ~ I CHs CHIs \ F ~ I CHs CH j i \ I CHs
N CHs ~l ~ ~ N N
CHs CHs 'F " CHs
Compound 55 Compound 56 Compound 57
CI
NIi~NH CHs / / \ CHs
w
CHi w w i I CHs I ~ N \ NH N ~ N
I ~N CHs / \ \ /
CHs
CHs CHs
Compound 58 Compound 59 Compound 60
Hs
w I CI CI
NHw ~ \ / \ CHs \ / \ CHs
I i CHs N \ NH H N N _\ H H ~N
~ NH I CHs N~ CHs / \ /
I \ C' \ /
CHs CHs
Compound 61 Compound 62 Compound 63
Hs \ C
H-~O NH CH N vwNH2 H N ~NHZ
N I
H N CH ~CH
C 3 3 3
Compound 64 Compound 65 Compound 66
N Hs ( ~ NH~ ~ I NHZ
i i i
CHs NH I ~ ~ I \ NH I I \ NH I i
I ~ N i N
~~V~~CHs CH H
3 C 3
Compound 67 Compound 68 Compound 69
I ~ I ~ NH~ CI
/ \
I I - N Ii~N HZ
NH N \ NH NH2 H
N i CH3 \ f I N
CHs
Compound 70 Compound 71 Compound 72
H NH NH I N~NH I Nl~~iwNH
s N
I \ ~N~N CH B~ ~ I Br w
CH3N~ N
Compound 73 Compound 74 Compound 75
13



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
N~ I N ~ N ~.~,NH
I N~ .I N I N~'~~.,NH i N N
I ~ N N
Compound 76 Compound 77 Compound 78
CI
NNS--O N I 00 I I O ~JO
NH NH~ N~N~i'NH N~N~~NH
N N I CI
Compound 79 Compound 80 Compound 8~~J1
O
O=Q~q ,O O O~Q F l
Br NI I N~N.~NH N NI~N.~NH 0. I NF~N~NH
N / F
Br I
Compound 82 Compound 83 Compound 84
CI O O~ I~ O
I N~''N'~NH I N~N/'\~~NH ~ ~N~NH
N~ ~CI CI
~1 I CI ~1 N N
Compound 85 Compound 86 Compound 87
O ~~~Br
CI ~S=O CI ~~O '~J~
~'N~'~-N H / ~ N
NH NH-~'' "~-NH NH N
N~ / N N
CI CI
Compound 88 Compound 89 Compound 90
O O
CI~ O
N~N"~-NH N~~NH N' H ~NH
N 1~~ ' N
N- \ N
CI CI
Compound 91 Compound 92 Compound 93
~~Q
~ro
N
CI l--~ '--~ CI
~N NH NH ~
t~t--~ _N
Compound 94 Compound 95 Compound 9b
14



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
,N
O ~ ~ / I ~ I I' \ CI
N~NH N~NH N~NH
CI~ CI~~~~
l ~ ~I
N N
Compound 97 Compound 98 Compound 99
Compound 100 Compound 101 Compound 102
F I~ I
~NH O N ~~O I N
CI NH ,S'O ~ NFi~N'~NH N~N~NH I
CI I ~ I CI I
N F
Compound 103 Compound 104 Compound 105
D'
I~
O.$.O N O. .O N
NFi~N'~NH I' NHS '~NH I
CI I % / I CI I ~ i i
N N
Compound 106 Compound 107 Compound 108
~+
I
NON I N~NH
~N' ~ I ~N~ w
I N+
I
Compound 109 Compound I 10 Compound 111
I
~N+ I
w N ~~NH I
Compound 112 Compound 113 Compound 114
15



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
0.
Br~ O
N NH N~NH' wN+. CI \ NH/~NfNH CI /N+ N~fV~ H /
\ ' \ N+
1
Compound 115 Compound 116 Compound 117
0. '
~C? ~ I 0. cl H
N~N~N H
N \ I ~ 1
~N+\ N~N~ ( + / ,N I / + ~t~+ NH N ~ ~N'
CI
CI CI
Compound 118 Compound 119 Compound 120
CI HO
I O 1
'N+ I I w
N H-~'J ~-N H / N ~N I +
~N / N N~H
Compound 121 Compound 122 Compound 123
/I
I
w +
N I N ~N I C
I rv, I ~ +N:
I
Compound 124 Compound 125 Compound 126
I~ I
0~ .O I ~N+~ ~~ I ~N+
NHS ~NH ' I CI N N'~NH I_
CI~ Ch~\~~~ i
I + CI lI + GI
I
Compound 127 Compound 128 Compound 129
D'
I
i CI I i ~ GI
NI~~NH I I N ~N I C N ~NH
CI I I N\ ~ I I N
I
Compound 130 Compound 131 Compound 132
16



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
N~
I / / CI I ~ CI
NH~'NH N~NH
y
CL~\5
i N+ lI N
Compound l33 Compound 134 Compound 135
Compound 136 Compound 137 Compound 138
Compound 139 Compound 140 Compound 141
N~N~N I ~ ~ w N~N~NH ~ / CI I NI~N.~NH
~g ~ I ~ I N ,N O N.
~O ~ O
N ~ CI
Compound 142 Compound 143 Compound 144
Fko 0. ~ I o ~ I ~°~ o
0
N~N.~ N ~N.~N I ~ I N~ .~N
N. ~ ~F ~ I ~N Cl~a~ N
IF wN~ 6 I N
Compound 145 Compound 146 Compound 147
17



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
,C I i $ O CI , I j CO C\ ,
N~N~NH I i F NH~N~NH I Nt~~vl~N./~NH I
CI ~ I ~ I ~N CI \ I I N CI \ I I ~N
N N
Compound 148 Compound 149 Compound I50
CI ~ I
~ ~ f,S,O,O \ ~ ~ S I o C N S I S>O w
N ~N~NH I i ~ N~~~N w ~ Nt~N~H I
C ~ ~ ,N N H ~ CI , I ~ I ~N
Cl ~ N
Compound 151 Compound 152 Compound 153
N ~ ~N~O , CO CI
H ~S H s ~~o ~ ~1 s= I
N N~ \ I I N~N~N N ~N~H I
N H I H ICIi w N
CI CI ~CI CI
Compound 154 Compound 155 Compound 156
Br
Br ~ I $p
H
N.~~N
H I
I CI
Compound 157 . Compound 159
dcHs
H3 0, o
I
I N ~N~NHI W
IOI ~N
CI
Compound 161 t,ompuunu ioc
Compound 163 Compound 164 Compound t65
1$



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
N
CH
Compound 169 Compoand 170 Compound 171
_CH3 ,CH3 dCH3
i
~1~0 O=~O O=~S--O NHy
~N~NH, I N ~N~NH~ CH3 N ~N~NH
CI p00 N~ B~ ~ CI IOI N ~ ~ CI IOI I i
CH~ CH~
Compound 172 Compound 173 Compound 174
Compound 175 Compound 176
CH3
H3
N' I ~~S~'O NHp
NH~N~NH~N
IOI Ui
CI
N
CI~
I N
Compound 178 Compound 179 Compound 180
Compound 181 Compound 182 compound t 2i3
19
Compound 166



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
CH3 CH3
y I w
i
~~° N ~ I 11~
N ~N~N N ~ N ~N~NHI I
CI ~ ~O i
CI~CH H ~ ~N I CH3
3
Compound 184 Compound 185 Compound 186
NHp NHZ
H H
I I ,
CI NOz
Compound l87 Compound 188 Compound Itiy
NH
CI
N
Compound 190
The scheme below depicts the syntheses of exemplary aminoquinoline
compounds, i.e., compounds 1-190. Details of preparation of these compounds
are
provided in Examples 1-190, respectively.
Rs s Q Rs CI
R I + ~~ Rs I Rp'~ Rs I s I Rz Rs I ~Rz
R~~NHz R R~ NJ~Rt R N R R~'~YRt
Ra z Re H ~ Ra ~ Re
Rs I
R_E Rs I Rz
R~ N Rt
Rs R E_
Route I
Linker R Linker R
Rs I Rs Rs Rs s Rz R s Rs
Rs Rz Linker Rs Rz R i ~ s
R7 I N Rt Rz I N Rt Rt ~l R7 R7 8 I" Rt t ~+ s R7
RB R8 88
compoandst-sz,74-96,US.las,tst-ISS,and157: Compound5110-122:
each of Rt and R=, indeprntrntly, is H, altyl, each of Rt and R=,
indepentcntly, is H or methyl;
or aryl; or Rt and R= together are cycba0cyl; and or Rt and R: together arc
cyclohcxyl;
each of R" Ry R,, and Rr, independently, is each of Rs, Ra, R,, and Re,
independently, is H,
H, F, CI, Br, OH. met6y4 ethyl. butyl, mdhoxy, CI, or mcthy; and
benzoxy, methylthio, or morphobn-4-yl. R is methyl, othyl, or hydroxycthyl.



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Route II
3 i
R4 RZ
Llnkef Compound.3lfi3,9B-I09,Ia6150,mtdl3k
Linker R R3 aarnnrR,.mRt,ma~.nmdy.aHam.myn
s i RS RS Rt' S aRt.ndRtmgdMerecycldsxyl:
Rg Ry Rg Rp R ~ Rg Ry Rz R< ercnvfRy,RbRhendRS,iMcycNendy,i.
Linker g I tl,cLmrNytahcnmxy
R7 N Rt Rt' N R5 ~nnarR;.mR;,ima,xmamdy,i.lt,m.d.yt,
R7 Rt R7 N Rt R , ~d~xy,n."m"r.rNylao-ilm.rem.a,yt:..a
Rg g 3 i Rg g ~n.rR;.R,'.R;,.naR;.mdm~mH.ia
R4 I RZ H. CI. F, rtearyl. Y, a hevexy.
RS N; Rt' ~ ~ cort~ undo 1:11.1:
g' R ..nnorR,.naR:,l.a~l,c.umty,hH..m.myl;
Linker R5 Linke aRi.ndRrmaruKr.rerydnn.xyL
Ra R R 3 R4 <sh of 0.y. RN Rr, ereS R.. indcpcndcrNy, is ll,
CL F. rtcNyL m brnmxy;
Rg R2 R2 R4' I R t .a~nof Rt e,dR;.indcpctdmlly,uHvr
I R7 Rt t 5 mnnYl:
R7 Rt Rt' ~ RS 8 RE R Rg ..~n~rR;.R"'.R;..naR;.inarP~na."tly.ia
R ~ a H,cLnrm.nyL.na
R is rteUyl. nnYL or hydrezxNyl.
Crenpund.l3blJd:
cxh orRt and Rr'vidn,rntmdy, a 11 a nnhyl: a R~ pod Rr tugsrha ere cycbhcxyt
.xh of fty, Ry Rv eM R., iMcpeodrndy, i. t4 C4 a mcdiyl:
each of R,' end Rr; ivdeperdendy, is H or mahyl; or Rj end Rj roaeJsrere
cyclohoeyl; eoch ofRy; R;, Rr; end Re; ma~Pr'vdrntly, is FI, CI, m methyl; end
R ia",~hyl.
Route III
R i RS Linker RS LinkerR ~~R a~~~'~'d'~m n~y5sH9o mead;
Rg RZ Rg Rp Rg ~ ~R2 mR~andRylognherarecyclohexyl:
I Linker I I ~~( °~~ each ufRy, Hy, R" and R" indcpcrtdently, is
R7 N Rt R7 N Rt R~'~~~~~Rt H,cLmctnyLorbenzoxy;ana
R is alkyl, aryl heteroaryl, heW ucycloaltyt, or
R8 8 Rg dipenylacetal.
Compounds 65, 66. 69. 7l. and 72:
tech ofRt and R=, indepentently,is H or
methyl; or Rt artd R= to8etner are cyclonezyl;
arM each of Ry, R., R,, and Ry, ivdependrntly,
a H, CI, mtthy4 or baaozy.
Route IV
N H R campnunds as am s7:
Rg I RS each fR~ aM Rr indepentently. is II or meNYl;
R R2 RNHp Rg RZ cash nfRy, Ra, Rr, and R" imependmdy, is
I H or mcNyl, and
R7 N Rt R7 N°~'Rt R is Niarol-= yhaminn-salronyl-phen-a-y
Rg g 9r2-clH.inanl-3-yl>-nlmL
For example, refernng to the scheme shown above, an aniline derivative is
reacted with a ~i-keto ester to produce an enamine. A quinolinone derivative
is
1 o formed through a ring closure reaction by heating the enamine at a high
temperature
for a short period time, and is then converted to a 4-chloro-quinoline
derivative upon
reacting with phosphorus oxychloride. A compound described in the summary
section above can be obtained by (1) reacting the 4-chloro-quinoline
derivative with a
linker containing at least two amino groups in a 2/1 ratio (Route I), (2)
reacting the 4-
~ 5 chloro-quinoline derivative with a linker in a 1 / 1 ratio and then with
another chloro-
containing compound in a 1/1 ratio (Routes II and III), or (3) reacting the 4-
chloro-
quinoline derivative with an amino-containing compound (Route IV).
21



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Other amionquinoline compounds can be prepared using other suitable starting
materials following the synthetic routes disclosed herein and other synthetic
methods
known in the art. The methods described above may also additionally include
steps,
either before or after the steps described specifically herein, to add or
remove suitable
protecting groups in order to ultimately allow synthesis of the aminoquinoline
~o compounds. In addition, various synthetic steps may be performed in an
alternate
sequence or order to give the desired compounds. Synthetic chemistry
transformations and protecting group methodologies (protection and
deprotection)
useful in synthesizing applicable aminoquinoline compounds are known in the
art and
include, for example, those described in R. Larock, Comprehensive Organic
~5 Transformations, VCH Publishers (1989); T.W. Greene and P.CzM. Wuts,
Protective
Groups in Organic Synthesis, 2nd Ed., John Wiley and Sons (1991); L. Fieser
and M.
Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and
Sons
(1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis,
John
Wiley and Sons (1995) and subsequent editions thereof.
2o The aminoquinoline compounds mentioned herein may contain a non-aromatic
double bond and one or more asymmetric centers. Thus, they can occur as
racemates
and racemic mixtures, single enantiomers, individual diastereomers,
diastereomeric
mixtures, and cis- or trans- isomeric forms. All such isomeric forms are
contemplated.
25 Also within the scope of this invention is a pharmaceutical composition
contains an effective amount of at least one aminoquinoline compound described
above and a pharmaceutical acceptable carrier. Further, this invention covers
a
method of administering an effective amount of one or more of the
aminoquinoline
compounds to a patient with an inflammatory or immune disease. Effective doses
3o will vary, as recognized by those skilled in the art, depending on the
types of diseases
treated, route of administration, excipient usage, and the possibility of co-
usage with
other therapeutic treatment.
To practice the method of the present invention, a composition having one or
more aminoquinoline compounds can be administered parenterally, orally,
nasally,
35 rectally, topically, or buccally. The term "parenteral" as used herein
refers to
subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular,
intraarterial,
22



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
intrasynovial, intrasternal, intrathecal, intralesional, or intracranial
injection, as well
as any suitable infusion technique.
A sterile injectable composition can be a solution or suspension in a non-
toxic
parenterally acceptable diluent or solvent, such as a solution in 1,3-
butanediol.
Among the acceptable vehicles and solvents that can be employed are mannitol,
~o water, Ringer's solution, and isotonic sodium chloride solution. In
addition, fixed oils
are conventionally employed as a solvent or suspending medium (e.g., synthetic
mono- or diglycerides). Fatty acid, such as oleic acid and its glyceride
derivatives are
useful in the preparation of injectables, as are natural pharmaceutically
acceptable
oils, such as olive oil or castor oil, especially in their polyoxyethylated
versions.
~ 5 These oil solutions or suspensions can also contain a long chain alcohol
diluent or
dispersant, carboxymethyl cellulose, or similar dispersing agents. Other
commonly
used surfactants such as Tweens or Spans or other similar emulsifying agents
or
bioavailability enhancers which are commonly used in the manufacture of
pharmaceutically acceptable solid, liquid, or other dosage forms can also be
used for
2o the purpose of formulation.
A composition for oral administration can be any orally acceptable dosage
form including capsules, tablets, emulsions and aqueous suspensions,
dispersions, and
solutions. In the case of tablets, commonly used carriers include lactose and
corn
starch. Lubricating agents, such as magnesium stearate, are also typically
added. For
25 oral administration in a capsule form, useful diluents include lactose and
dried corn
starch. When aqueous suspensions or emulsions are administered orally, the
active
ingredient can be suspended or dissolved in an oily phase combined with
emulsifying
or suspending agents. If desired, certain sweetening, flavoring, or coloring
agents can
be added.
3o A nasal aerosol or inhalation composition can be prepared according to
techniques well known in the art of pharmaceutical formulation. For example,
such a
composition can be prepared as a solution in saline, employing benzyl alcohol
or
other suitable preservatives, absorption promoters to enhance bioavailability,
fluorocarbons, and/or other solubilizing or dispersing agents known in the
art. A
35 composition having one or more active aminoquinoline compounds can also be
administered in the form of suppositories for rectal administration.
23



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
The carrier in the pharmaceutical composition must be "acceptable" in the
sense that it is compatible with the active ingredient of the composition (and
preferably, capable of stabilizing the active ingredient) and not deleterious
to the
subject to be treated. One or more solubilizing agents can be utilized as
pharmaceutical excipients for delivery of an active aminoquinoline compound.
~ o Examples of other carriers include colloidal silicon oxide, magnesium
stearate,
cellulose, sodium lauryl sulfate, and D&C Yellow # 10.
The aminoquinoline compounds of this invention can be preliminarily
screened for their efficacy in treating inflammatory or immune diseases by an
in vitro
assay (See Example 191 below) and then confirmed by animal experiments and
~ 5 clinical trials. Other methods will also be apparent to those of ordinary
skill in the art.
The specific examples below are to be construed as merely illustrative, and
not
limitative of the remainder of the disclosure in any way whatsoever. Without
further
elaboration, it is believed that one skilled in the art can, based on the
description
herein, utilize the present invention to its fullest extent. All publications
cited herein
2o are hereby incorporated by reference in their entirety.
Example 1
Compound 1 was prepared following the procedures described below:
p-Toluenesulfonic acid (catalytic amount) was added to a solution ofp-
25 methylaniline (10.7 g, 100 mmol) and ethyl acetoacetate (13.0 g, 110 mmol)
in
benzene (250 mL) at room temperature. The reaction mixture was refluxed with a
Dean-Stark apparatus over night. After cooling down to room temperature, the
reaction mixture was concentrated and purified by column chromatography (5%
ethyl
acetate in n-hexane) to give 3 p-tolylamino-but-2-enoic acid ethyl ester (18.6
g, 85
3o yield).
3 p-Tolylamino-but-2-enoic acid ethyl ester (21.9 g, 100 mmol) thus obtained
was dissolved in phenyl ether (17.0 g, 100 mmol). The solution was heated to
120 °C
for 5 minutes. The temperature of reaction mixture was then quickly raised up
to 250
°C for 15 min under nitrogen. After cooling down to room temperature,
the reaction
s5 mixture was purified by re-crystallization from ethyl acetate (30 mL) to
give 2,6-
dimethyl-1H-quinolin-4-one (13.8 g, 80 % yield).
24



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
A mixture of 2,6-dimethyl-1H-quinolin-4-one (17.3 g, 100 mmol) and
phosphorus oxychloride (30 mL) was heated at 80 °C for 3 h. After
cooling down to
room temperature, the reaction mixture was poured onto ice. The resulting
solution
was carefully alkalinized to pH 8-9 with 0.5 N NaOH and saturated Na2C03. The
solution was extracted with CHzCl2 (200 mL x 3). The organic layer was
separated,
o dried over magnesium sulfate, and concentrated under reduced pressure. The
crude
product was purified by column chromatography (10% ethyl acetate in n-hexane)
to
give 4-chloro-2,6-dimethyl-quinoline (12.4 g, 65 % yield).
4-Chloro-2,6-dimethyl-quinoline (211 mg, 1.1 mmol) and 1,4-butadiamine
(44 mg, 0.5 mmol) were dissolved in pentanol (5 mL). The solution was kept
under
~ 5 reflux over night. After cooling down to room temperature, 0.5 N NaOH (S
mL) was
added to the above reaction mixture. The reaction mixture was stirred at room
temperature for another 30 minutes and then extracted with CHZCl2 (10 mL x 3).
The
organic layer was separated, dried over magnesium sulfate, and concentrated
under
reduced pressure. The crude product was then purified by column chromatography
20 (2% Et3N in 1:1 n-hexane and ethyl acetate) to give compound 1.
LC1MS (M+1)+: 399Ø
Example 2
Compound 2 was prepared in a manner similar to that described in Example 1.
25 LC/MS (M+1)+: 427Ø
Example 3
Compound 3 was prepared in a manner similar to that described in Example 1.
LC/MS (M+1)+: 441Ø
Example 4
Compound 4 was prepared in a manner similar to that described in Example 1.
LC/MS (M+1 )+: 469.1.
Example 5



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Compound 5 was prepared in a manner similar to that described in Example 1.
LC/MS (M+1)+: 413.1.
Example 6
Compound 6 was prepared in a manner similar to that described in Example 1.
1o LC/MS (M+1)+: 455Ø
Example 7
Compound 7 was prepared in a manner similar to that described in Example 1.
LC/MS (M+1)+: 431.1.
Example 8
Compound 8 was prepared in a manner similar to that described in Example 1.
LC/MS (M+1)+: 459Ø
2o Example 9
Compound 9 was prepared in a manner similar to that described in Example 1.
LC/MS (M+1)+: 461.2.
Example 10
Compound 10 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 447.2.
Example 11
3o Compound 11 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 611.2.
Example 12
Compound 12 was prepared in a manner similar to that described in Example
1.
26



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
LC/MS (M+1)+: 597.2.
Example 13
Compound 13 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 583.2.
Example 14
Compound 14 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 569.2.
Example 15
Compound 1 S was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 463.1.
Example 16
Compound 16 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 477.1.
Example 17
Compound 17 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 491.1.
Example 18
Compound 18 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 435.1.
Example 19
27



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Compound 19 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 466.9.
Example 20
1o Compound 20 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 556.8.
Example 21
Compound 21 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 481.2.
Example 22
Compound 22 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 511.3.
Example 23
Compound 23 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 736.8.
Example 24
Compound 24 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 615Ø
Example 25
Compound 25 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 479.2.
28



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 26
Compound 26 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 493.1.
Example 27
Compound 27 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 507.3.
Example 28
Compound 28 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 507.1.
2o Example 29
Compound 29 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 599.1.
Example 30
Compound 30 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 469Ø
3o Example 31
Compound 31 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 463.1.
Example 32
29



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Compound 32 was prepared in a manner similar to that described in Example
1.
LClMS (M+1)+: 384.9.
Example 33
Compound 33 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 447.2.
Example 34
Compound 34 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1 )+: 419.1.
Example 35
2o Compound 35 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 469.2.
Example 36
Compound 36 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 471.2.
Example 37
Compound 37 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 562Ø
Example 38
Compound 38 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1 )+: 523Ø



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 39
Compound 39 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 559.2.
Example 40
Compound 40 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1 )+: 414.2.
Example 41
Compound 41 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 584Ø
Example 42
Compound 42 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 554Ø
Example 43
Compound 43 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 568Ø
Example 44
Compound 44 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 633.9.
Example 45
31



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Compound 45 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 431.2.
Example 46
Compound 46 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1 )+: 563.1.
Example 47
~5 Compound 47 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1 )+: 652.8.
Example 48
2o Compound 48 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 454Ø
Example 49
25 Compound 57 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 598.1.
Example 50
3o Compound 50 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 611.9.
Example 51
35 Compound 51 was prepared in a manner similar to that described in Example
1.
32



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
LC/MS (M+1)+: 623.9.
Example 52
Compound 52 was prepared in a manner similar to that described in Example
1.
~o LC/MS (M+1)+: 634Ø
Example 53
Compound 53 was prepared following the procedures described below:
4-Chloro-2,6-dimethyl-quinoline (1.9 g, 10 mmol) obtained in Example l and
1,6-hexadiamine (2.3 g, 20 mmol) were dissolved in pentanol (40 mL). The
solution
~ 5 was kept under reflux over night. After cooling down to room temperature,
0.5 N
NaOH (5 mL) was added to the reaction mixture. The reaction mixture was
stirred at
room temperature for 30 minutes and then extracted with CHZC12 (10 mL x 3).
The
organic layer was separated, dried over magnesium sulfate, and concentrated
under
reduced pressure. The crude product was purified by column chromatography (2%
2o Et3N in 1:2 n-hexane and ethyl acetate) to give N1-(2,6-dimethyl-quinolin-4-
yl)-
hexane-1,5-diamine (1.9 g, 70% yield).
N1-(2,6-Dimethyl-quinolin-4-yl)-hexane-1,5-diamine (271 mg, 1.0 mmol)
thus obtained, 4-chloro-6-methoxy-2-methyl-quinoline (228 mg, 1.1 mmol)
(obtained
following the procedure described in Example 1), and sodium iodide (catalytic
25 amount) were added in pentanol (10 mL). The reaction mixture was kept under
reflux
over night. After cooling down to room temperature, 0.5 N NaOH (5 mL) was
added
to the reaction mixture. The reaction was stirred at room temperature for
another 30
minutes and then extracted with CHZC12 (10 mL x 3). The organic layer was
separated, dried over magnesium sulfate, and concentrated under reduced
pressure.
3o The product was purified by column chromatography (2% Et3N in 1:1 n-hexane
and
ethyl acetate) to give compound 53.
LClMS (M+1)+: 430.2.
Example 54
35 Compound 54 was prepared in a manner similar to that described in Example
53.
33



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
LC/MS (M+1)+: 519.2.
Example 55
Compound 55 was prepared in a manner similar to that described in Example
53.
~ o LC/MS (M+1 )+: 427.2.
Example 56
Compound 56 was prepared in a manner similar to that described in Example
53.
~ 5 LC/MS (M+1 )+: 467.2.
Example 57
Compound 57 was prepared in a manner similar to that described in Example
53.
2o LC/MS (M+1)+: 453.2.
Example 58
Compound 58 was prepared in a manner similar to that described in Example
53.
25 LC/MS (M+1)+: 467.2.
Example 59
Compound 59 was prepared in a manner similar to that described in Example
53.
3o LC/MS (M+1)+: 615Ø
Example 60
Compound 60 was prepared in a manner similar to that described in Example
53.
35 LC/MS (M+1)+: 543.2.
34



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 61
Compound 61 was prepared in a manner similar to that described in Example
53.
LCIMS (M+1)+: 537.2.
o Example 62
Compound 62 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 546.2.
~ 5 Example 63
Compound 63 was prepared in a manner similar to that described in Example
53.
LCiMS (M+1)+: 635.2.
Example 64
2o Compound 64 was prepared following the procedures described below:
4-Chloro-2,6-dimethyl-quinoline (191 mg, 1.0 mmol) obtained in Example 1
and 4-amino-N-thiazol-2-yl-benzenesulfonamide (280 mg, 1.1 mmol) were
dissolved
in pentanol (5 mL). The solution was kept under reflux over night. After
cooling
down to room temperature, 0.5 N NaOH (5 mL) was added to the reaction
solution.
25 The reaction mixture was stirred at room temperature for another 30 minutes
and then
extracted with CHZCl2 (10 mL x 3). The organic layer was separated, dried over
magnesium sulfate, and concentrated under reduced pressure. The crude product
was
purified by column chromatography (2% Et3N in ratio 1:1 n-hexane and ethyl
acetate)
to give compound 64 (328 mg, 80 % yield).
3o LC/MS (M+1)+: 410.8.
Example 65
Compound 65 was prepared following the procedures described in the first
paragraph of Example 53.
35 LC/MS (M+1)+: 272Ø



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 66
Compound 66 was prepared in a manner similar to that described in the first
paragraph of Example 53.
LC/MS (M+1)+: 258.2.
~o Example 67
Compound 67 was prepared in a manner similar to that described in Example
64.
LC/MS (M+1)+: 316.1.
~5 Example 68
Compound 68 was prepared following the procedures described below:
Pyridine-2-carbaldehyde (210 mg, 1.1 mmol), {2-[2-(2-amino-phenyl)-ethyl]-
phenyl}-(2,6-dimethyl-quinolin-4-yl)-amine (367 mg, 1.0 mmol) (This compound
was prepared in a manner similar to that described in step 1 of Example 53.),
and 10
2o wt% Pd/C (catalytic amount) were dissolved in MeOH (20 mL). The reaction
mixture
was kept under pressure (60 psi) with HZ over night. After releasing the
pressure, the
reaction mixture was filtered and concentrated. The crude product was purified
by
column chromatography (2% Et3N in 1:1 n-hexane and ethyl acetate) to give
compound 68 (459 mg, 85% yield).
25 LC/MS (M+1)+: 459Ø
Example 69
Compound 69 was prepared in a manner similar to that described in the first
paragraph of Example 53.
so LC/MS (M+1)+: 460.1.
Example 70
Compound 70 was prepared in a manner similar to that described in Example
68.
35 LC/MS (M+1)+: 551.2.
36



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 71
Compound 71 was prepared in a manner similar to that described in the first
paragaph of Example 53.
LClMS (M+1)+: 387.1.
o Example 72
Compound 72 was prepared in a manner similar to that described in the first
paragaph of Example 53.
LC/MS (M+1)+: 298.2.
~5 Example 73
Compound 73 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 443.2.
2o Example 74
Compound 74 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 651.1.
25 Example 75
Compound 75 was prepared in a manner similar to that described in Example
1.
LCJMS (M+1)+: 535.1.
3o Example 76
Compound 76 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 479.3.
37



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 77
Compound 77 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 563.4.
o Example 78
Compound 78 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 495.3.
~5 Example 79
Compound 79 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 572.2.
2o Example 80
Compound 80 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 598.3.
25 Example 81
Compound 81 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 638.1.
Exam lp a 82
3o Compound 82 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 756.1.
Example 83
35 Compound 83 was prepared in a manner similar to that described in Example
1.
38



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
LC/MS (M+1)+: 630.2.
Example 84
Compound 84 was prepared in a manner similar to that described in Example
1.
~o LC/MS (M+1)+: 634.2.
Example 85
Compound 85 was prepared in a manner similar to that described in Example
1.
~5 LClMS (M+1)+: 546.1.
Example 86
Compound 86 was prepared in a manner similar to that described in Example
1.
2o LC/MS (M+1)+: 614.1.
Example 87
Compound 87 was prepared in a manner similar to that described in Example
1.
25 LC/MS (M+1)+: 612.2.
Example 88
Compound 88 was prepared in a manner similar to that described in Example
1.
so LC/MS (M+1)+: 652.1.
Example 89
Compound 89 was prepared in a manner similar to that described in Example
1.
35 LC/MS (M+1)+: 692.3.
39



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 90
Compound 90 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 702Ø
o Example 91
Compound 91 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 616.2.
~ 5 Example 92
Compound 92 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 560.2.
2o Example 93
Compound 93 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 600.3.
25 Example 94
Compound 94 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 588.2.
3o Example 95
Compound 95 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 666.2.



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 96
Compound 96 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 574.2.
~ o Example 97
Compound 97 was prepared in a manner similar to that described in the first
paragraph of Example 53, the intermediate thus obtained was then treated with
biphenylacetyl chloride and worked up following the procedures described in
Example 68.
LC/MS (M+1)+: 528.1.
Example 98
Compound 98 was prepared in a manner similar to that described in Example
53.
2o LC/MS (M+1)+: 502.1.
Example 99
Compound 99 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 508.5.
Example 100
Compound 100 was prepared in a manner similar to that described in Example
53.
so LC/MS (M+1)+: 629.3.
Example 101
Compound 101 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 636.2.
41



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 102
Compound 102 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 674.1.
1o Example 103
Compound 103 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 622.2.
Example 104
Compound 104 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 636.2.
Example 105
2o Compound 105 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 650.2.
Example 106
Compound 106 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 688.1.
Example 107
3o Compound 107 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 692.2.
Example 108
Compound 108 was prepared in a manner similar to that described in Example
53.
42



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
LC/MS (M+1)+: 686.2.
Example 109
Compound 109 was prepared in a manner similar to that described in Example
53.
~o LC/MS (M+1)+: 580.2.
Example 110
Compound 110 was prepared following the procedures described below:
Compound 26 (160 mg) and methyl iodide (460 mg) were added in 3 mL of
~ 5 THF and the mixture was refluxed for 3 hours. The precipitate thus
obtained was
collected by filtration, washed with ether, and dried to give the desired
product.
LC/MS (M-1)+: 520.2.
Example 111
2o Compound 111 was prepared in a manner similar to that described in Example
110.
LC/MS (M-1)+: 455.7.
Example 112
Compound 112 was prepared in a manner similar to that described in Example
25 110.
LC/MS (M-1)+: 550.2.
Example 113
Compound 113 was prepared in a manner similar to that described in Example
30 110.
LC/MS (M-1)+: 579.3.
Example 114
Compound 114 was prepared in a manner similar to that described in Example
35 110.
LC/MS (M-1)+: 523.3.
43



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 115
Compound 115 was prepared in a manner similar to that described in Example
110.
LC/MS (M-1)+: 662.2.
~o
Example 116
Compound 116 was prepared in a manner similar to that described in Example
110.
LClMS (M-1)+: 666.2.
Example 117
Compound 117 was prepared in a manner similar to that described in Example
110.
LC/MS (M-1)+: 640.3.
Example 118
Compound 118 was prepared in a manner similar to that described in Example
110.
LC/MS (M-1)+: 680.2.
Example 119
Compound 119 was prepared in a manner similar to that described in Example
110.
3o LClMS (M-1)+: 720.4.
Example 120
Compound 120 was prepared in a manner similar to that described in Example
110.
LC/MS (M-1)+: 588.2.
44



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 121
Compound 121 was prepared in a manner similar to that described in Example
110.
LC/MS (M-1)+: 644.3.
~ o Example 122
Compound 122 was prepared in a manner similar to that described in Example
110.
LC/MS (M-1 )+: 616.2.
Example 123
Compound 123 was prepared following the procedures described below:
Compound 54 (160 mg) was added in 5 mL of 2-iodoethanol and the solution
was refluxed for 3 hours. The precipitate thus formed was collected by
filtration,
washed with ether, and dried to give the desired product.
2o LC/MS (M-1)+: 607.8.
Example 124
Compound 124 was prepared in a manner similar to that described in Example
123.
LC/MS (M-1)+: 547.8.
Example 125
Compound 125 was prepared in a manner similar to that described in Example
123.
LC/MS (M-1)+: 664.2.
Example 126
Compound 126 was prepared in a manner similar to that described in Example
123.
LC/MS (M-1)+: 678.2.
Example 127



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Compound 127 was prepared in a manner similar to that described in Example
123.
LC/MS (M-1)+: 702.1.
Example 128
Compound 128 was prepared in a manner similar to that described in Example
123.
LC/MS (M-1)+: 720.2.
Example 129
~5 Compound 129 was prepared in a manner similar to that described in Example
123.
LC/MS (M-1)+: 714.3.
2o Example 130
Compound 130 was prepared following the procedures described below:
Methyl iodide (3 mL) and 4,6-dichloro-2-methylquinoline (2 g) were heated in
CH3CN at 65 ° C for 40 hours. The precipitate thus formed was
collected by
filtration, washed with ether, and dried by nitrogen flow and by vacuum to
give a
25 quaternary quinolinium salt (2.1 g).
Compound 81 (92.8 mg) and quinolinium salt (70.9 mg) obtained above were
added in 3 mL of CH3CN. The mixture was refluxed for 12 hours. The
precipitation
thus obtained was collected by filtration, washed with ether, and dried to
give the
desired product.
3o LC/MS (M)+: 652.2.
Example 131
Compound 131 was prepared in a manner similar to that described in Example
130.
35 LC/MS (M)+: 515.
46



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 132
Compound 132 was prepared in a manner similar to that described in Example
130.
LC/MS (M)+: 481.2.
~o Example 133
Compound 133 was prepared in a manner similar to that described in Example
130.
LC/MS (M)+: 521.2.
~5 Example 134
Compound 134 was prepared in a manner similar to that described in Example
130.
LC/MS (M)+: 521.2.
Example 135
2o Compound 135 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 643. '
Example 136
25 Compound 136 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 691.
Example 137
3o Compound 137 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 612.
Example 138
35 Compound 138 was prepared in a manner similar to that described in Example
1.
47



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
LC/MS (M+1)+: 642.
Example 139
Compound 139 was prepared in a manner similar to that described in Example
1.
~ o LC/MS (M+1 )+: 642.
Example 140
Compound 140 was prepared in a manner similar to that described in Example
1.
~5 LC/MS (M+1)+: 682.
Example 141
Compound 141 was prepared in a manner similar to that described in Example
1.
2o LC/MS (M+1 )+: 642.
Example 142
Compound 142 was prepared in a manner similar to that described in Example
1.
25 LC/MS (M+1)+: 662.8.
Example 143
Compound 143 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1 )+: 704.7.
Example 144
Compound 144 was prepared in a manner similar to that described in Example
1.
LClMS (M+1)+: 667.5.
48



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 145
Compound 145 was prepared in a manner similar to that described in Example
1.
LC/MS (M+1)+: 738.4.
0 Example 146
Compound 146 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 673.1.
Example 147
Compound 147 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 665Ø
2o Example 148
Compound 148 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 657.4.
Example 149
Compound 149 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 625.4.
3o Example 150
Compound 150 was prepared in a manner similar to that described in Example
53.
LC/MS (M+1)+: 635.1.
Example 151
3s Compound 151 was prepared in a manner similar to that described in Example
1.
49



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
LC/MS (M+1)+: 653.4.
Example 152
Compound 152 was prepared in a manner similar to that described in Example
1.
~ o LClMS (M+1 )+: 720.8.
Example 153
Compound 153 was prepared in a manner similar to that described in Example
1.
~5 LC/MS (M+1)+: 682.6.
Example 154
Compound 154 was prepared in a manner similar to that described in Example
1.
2o LC/MS (M+1)+: 656.6.
Example 155
Compound 155 was prepared in a manner similar to that described in Example
1.
25 LC/MS (M+1)+: 672.4.
Example 156
Compound 156 was prepared in a manner similar to that described in Example
53.
3o LC/MS (M+1)+: 725.6.
Example 157
Compound 157 was prepared in a manner similar to that described in Example
1.
35 LC/MS (M+1)+: 801.4.



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 158
Compound 158 was prepared following the procedures described below:
o A mixture of 3-[[2-(6-chloro-2-methyl-quinolin-4-ylamino)-ethyl]-(4-
methoxy-benzenesulfonyl)-amino]-propionic acid (100 mg) (This compound was
prepared in a manner similar to that described in step 1 of Example 53.) and 1-
[3-
(dimethylamino)-propyl]-3-ethylcarbodiimide hydrochloride (80 mg) was stirred
in
DMF (2 mL) for 30 minutes at room temperature, followed by addition of 4-amino-
N-
~ 5 (2,6-dimethyl-pyrimidin-4-yl)-benzenesulfonamide (64 mg). The reaction
mixture
was stirred for 3 hours, and then the solvent was evaporated under vacuum. The
residue was then quenched with H20 (2 mL) and extracted with CHC13 (10 mL).
The
combined extract was dried with MgS04, concentrated under vacuum, and purified
by
column chromatography to give compound 158.
2o LC/MS (M+1)+: 737.8.
Example 159
Compound 159 was prepared in a manner similar to that described in Example
158.
25 LC/MS (M+1)+: 595.8.
Example 160
Compound 160 was prepared in a manner similar to that described in Example
158.
3o LC/MS (M+1)+: 637.8.
Example 161
Compound 161 was prepared in a manner similar to that described in Example
158.
35 LC/MS (M+1)+: 553.9.
51



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 162
Compound 162 was prepared in a manner similar to that described in Example
158.
~ o LC/MS (M+1 )+: 610.9.
Example 163
Compound 163 was prepared in a manner similar to that described in Example
158.
LClMS (M+1)+: 660.1.
Example 164
Compound 164 was prepared in a manner similar to that described in Example
158.
2o LCIMS (M+1)+: 568.9.
Example 165
Compound 165 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 552.9.
Example 166
Compound 166 was prepared in a manner similar to that described in Example
158.
3o LC/MS (M+1)+: 609.1.
Example 167
Compound 167 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 597.1.
52



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 168
Compound 168 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 568.9.
Example 169
Compound 169 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 594.9.
Example 170
Compound 170 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 584.1.
Example 171
Compound 171 was prepared in a manner similar to that described in Example
68.
LC/MS (M+1)+: 604.1.
Example 172
Compound 172 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 604Ø
Example 173
Compound 173 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 568.1.
53



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 174
Compound 174 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 568Ø
Example 175
Compound 175 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 582.9.
Example 176
Compound 176 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 644.9.
Example 177
Compound 177 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 603.9.
Example 178
Compound 178 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 583.9.
Example 179
Compound 179 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 568.9.
54



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Example 180
Compound 180 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 554.1.
Example 181
Compound 181 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 569.1.
~ 5 Example 182
Compound 182 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 599.1.
2o Example 183
Compound 183 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 559.1.
25 Example 184
Compound 184 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 620.1.
3o Example 185
Compound 185 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 604.1.
Example 186



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
Compound 186 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 603.9.
Example 187
Compound 187 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 570.9.
Example 188
~ 5 Compound 188 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 601.9.
Example 189
2o Compound 189 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 613.1.
Example 190
25 Compound 190 was prepared in a manner similar to that described in Example
158.
LC/MS (M+1)+: 682.1.
Example 191
3o Compounds 1-190 were tested for their efficacy in blocking activation of
CXCR3 using a DELFIA GTP-binding kit (Wallac Oy, Turku, Finland). The
DELFIA GTP-binding assay is a time-resolved fluorometric assay based on GDP-
GTP exchange on G-protein subunits followed by activation of a G protein-
coupled
receptor by its agonists. Eu-GTP, obtained from Wallac Oy, was used in this
assay to
35 allow monitoring of agonist-dependent activation of G-protein. Stimulation
of
CXCR3 by interferon-oc inducible protein 10 (IP-10) leads to the replacement
of GDP
56



CA 02521619 2005-10-05
WO 2004/091485 PCT/US2004/010695
s by GTP on the a-subunit of G-protein. This GTP-Ga complex represents the
activated form of G-protein. Eu-GTP, a non-hydrolysable analog of GTP, can be
used
to quantify the amount of activated G-protein. (Peltonen et al., Eur. J.
Pharmacol.
(1998) 355:275.)
Plasma membrane of CXCR3-expressing HEK293 cells was suspended in an
o assay buffer (50 mM NaCI, 100 p.g/mL saponin, 3 mM MgClz, 3 pM GDP, 5% BSA,
50 mM HEPES, pH 7.4). An aliquot (4 pg protein) was added to each well of an
AcroPlate (Pall Life Sciences, Ann Arbor, MI). After the addition of the test
compounds (10 pM in 0.1% DMSO) and IP-10 (4 nM in the assay buffer), the assay
plate was incubated in the dark at room temperature with slow shaking for 10
~s minutes. Eu-GTP was added to each well and the plate was incubated again
for 60
minutes. The assay was terminated by washing the plate twice with a wash
solution
provided in the assay kit. Binding of Eu-GTP was determined based on the
fluorescence signal from a Victor 2 multi-label reader.
Unexpectedly, 92 compounds showed ICSO values lower than 1 pM, 33
2o compounds showed ICso values between 1 p,M and 5 pM, and 30 compounds
showed
ICso values between 5 p,M and 10 p.M.
OTHER EMBODIMENTS
All of the features disclosed in this specification may be combined in any
2s combination. Each feature disclosed in this specification may be replaced
by an
alternative feature serving the same, equivalent, or similar purpose. Thus,
unless
expressly stated otherwise, each feature disclosed is only an example of a
generic
series of equivalent or similar features.
From the above description, one skilled in the art can easily ascertain the
3o essential characteristics of the present invention, and without departing
from the spirit
and scope thereof, can make various changes and modifications of the invention
to
adapt it to various usages and conditions. Thus, other embodiments are also
within
the scope of the following claims.
57

Representative Drawing